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ABSTRACT 
Background & Aims: It is not clear whether alterations in the intestinal microbiota of children with 
celiac disease cause the disease or are a result of disease and/or its treatment with gluten-free diet 
(GFD). 
Methods: We obtained 167 fecal samples from 141 children (20 with new-onset celiac disease, 45 
treated with a GFD, 57 healthy children, and 19 unaffected siblings of children with celiac disease) in 
Glasgow, Scotland. Samples were analyzed by 16S rRNA sequencing and diet-related metabolites 
were measured by gas chromatography. We obtained fecal samples from 13 of the children with 
new-onset CD after 6 and 12 months on GFD. Relationships between microbiota with diet 
composition, gastrointestinal function, and biomarkers of GFD compliance were explored. 
Results: Microbiota α diversity did not differ among groups. Microbial dysbiosis was not observed in 
children with new-onset celiac disease. In contrast, 2.8% (Bray-Curtis dissimilarity index, P=.025) and 
2.5% (UniFrac distances, P=.027) of the variation in microbiota composition could be accounted for 
by the GFD. Between 3% to 5% of all taxa differed among all group comparisons. Eleven distinctive 
operational taxonomic units composed a microbe signature specific to celiac disease with high 
diagnostic probability. Most of the operational taxonomic units that differed between patients on 
GFD with new-onset celiac disease vs healthy children were associated with nutrient and food group 
intake (from 75% to 94%), and with biomarkers of gluten ingestion. Fecal levels of butyrate and 
ammonia decreased during the GFD.  
Conclusions: Although several alterations in the intestinal microbiota of children with established 
celiac disease appear to be effects of a GFD, there are specific bacteria that are distinct biomarkers 
of celiac disease. Studies are needed to determine whether these bacteria contribute to 
pathogenesis of celiac disease. 
 
Keywords: OTU, pediatric, microbiome, short chain fatty acids 
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INTRODUCTION 
Celiac disease (CD) is an autoimmune destruction of small intestinal villi triggered by ingestion of 
gluten in genetically susceptible individuals1. It causes nutrient malabsorption, leading to intestinal 
and extra-intestinal symptoms2. Lifelong adherence to a gluten-free diet (GFD) is the only treatment. 
The underlying pathogenesis of CD is multifactorial and while genetic predisposition occurs in 30-
40% of the general population, only a small proportion of these individuals will develop CD, 
suggesting that environmental factors are at play3. This premise is supported by the rise in the 
incidence of CD over past decades, suggesting that changes in population genetics cannot explain 
this increase, nor can changes in gluten consumption3. Weaning practices, antibiotic exposure4, 5, 
and viral gastrointestinal (GI) infections6 have been implicated as risk factors for CD onset7. Recent 
evidence points to the involvement of the gut microbiota8-17; driven by the rapid expansion of 
microbiota research.  
 Several non-communicable diseases, like inflammatory bowel disease, show increasing 
incidence similar to CD, and have been associated with distinct features of microbiota structure and 
function, also termed ‘dysbiosis’18. There has been increasing interest in research exploring the role 
of the microbiota in  CD. However, results remain inconclusive. Previous research was mostly of 
cross-sectional design providing a snapshot of the gut microbiota in CD and most importantly, did 
not determine whether a disturbed microbiota in feces of new-onset, untreated patients (UCD) is 
implicated in disease pathogenesis or is predominantly an epiphenomenon of the underlying 
disease, altered gastrointestinal (GI) motility and excessive substrate availability, owing to nutrient 
malabsorption and intestinal inflammation. Research has also described an altered microbiota in 
treated patients with CD (TCD) but did not explore the extent to which these signals were attributed 
to dietary modification and exclusions imposed during treatment with GFD. Studies describing the 
human fecal microbiota of CD using next-generation sequencing do not exist and previous research 
relied on characterization of selective microbial groups8-17.   
This study characterized the gut microbiota of children with CD. We combined cross-
sectional and prospective patient cohorts and collected data on determinants of the microbiota 
likely to change in children with CD during GFD, or likely to differ when comparing CD with healthy 
controls (HC). For the first time in the literature, we profiled the fecal microbiota using 16S rRNA 
gene sequencing and measured metabolites likely to be influenced by adherence to GFD. 
Additionally, we explored associations with dietary intake, GI symptoms and novel biomarkers of 
GFD compliance.  
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We hypothesized that the gut microbiota of CD patients differs from HC; several of these 
microbial signals are secondary effects of dietary modifications during GFD, but others may be 
implicated in the underlying disease pathogenesis.    
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MATERIAL & METHODS 
Subjects 
Fecal samples were collected from children with CD attending the Royal Hospital for Children in 
Glasgow. New-onset patients with CD were referred from primary healthcare services whereas 
previously diagnosed children were recruited from clinics which patients attend annually. Siblings of 
CD children with no clinical symptoms and negative tissue transglutaminase IgA antibodies (tTG-IgA), 
and healthy volunteers recruited via advertisement were used for comparative analysis. In these two 
groups, healthy status was defined as children who did not visit their general practitioner for a 
medical condition regularly or who did not receive regular medication, and who had no past history 
of chronic GI disorders. All consecutive children were invited to participate unless they met one of 
the exclusion criteria (i.e. antibiotics use or regular use of probiotics/prebiotics in the preceding 3 
months. Patients with other comorbidities were also excluded.  
Celiac disease was confirmed by small bowel biopsy using UK guidelines in place at the time 
of recruitment19. Dietary intake (macronutrient and food groups) was evaluated using a Scottish 
food frequency questionnaire (FFQ)20. GI symptoms were evaluated using the PedsQL-GS 
questionnaire (version 1)21. The higher the PedsQL-GS score, the lower GI symptoms are. Recent 
gluten ingestion, a proxy marker of GFD adherence, was evaluated by measuring the fecal gluten 
immunogenic peptide (GIP) levels (iVYLISA, Biomedal, Spain)22. 
 
Fecal sample collection  
The entire bowel movement was collected, stored under anaerobic (Anaerocult® A, Merck, 
Germany) cold conditions and processed within 2 hours of defecation. The entire sample was 
homogenized with a hand-blender and stored appropriately for downstream analysis. Except for the 
UCD patients a single sample was collected. For the UCD group we aimed to collect 3 samples; one 
baseline sample prior to diagnostic endoscopy while the patients were on a gluten-containing diet, 
and again at 6 and 12 months on GFD. 
 
Fecal water content, pH and ammonia 
Fecal pH was measured in aqueous slurries and fecal ammonia with an analyzer (Hanna HI 93715, 
Bedfordshire, United Kingdom)23. Fecal water content was calculated after lyophilization.  
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Microbiota profiling   
Genomic DNA was isolated using the chaotropic method within 3 months of sample collection24. 
Sequencing of the V4 region of the 16S rRNA gene was performed with MiSeq (Illumina) using the 
Golay barcodes on the reverse strand18, 25. Barcoded amplicons were purified using the Zymoclean 
Gel DNA Recovery Kit (D4001). 
 
Fecal SCFA, lactate and sulfide 
The short chain fatty acids (SCFA) acetic, propionic, butyric and valeric acids, and the branch chain 
fatty acids (BCFA) (isobutyric and isovaleric acids) were measured using gas chromatography (Agilent 
7820A) with a DB–WAX UI column on diethyl ether extracts23, 25. Nitrogen was the carrier gas. D- and 
L-lactate were measured using a commercial kit (D, L Lactic Acid, Roche, Cat No; 11112821035) 
scaled-down for use in a 96-well plate. Free and total sulfide were measured colorimetrically23. 
 
Bioinformatics analysis 
Quality trimming was done using Sickle, applying a sliding window approach and trimming regions 
where average base quality (PHRED score) dropped below 2026. Assembly of paired reads was done 
using PANDAseq27. USEARCH was used for dereplication and clustering of sequences into operational 
taxonomic units (OTUs) of 97% similarity as described in 
https://docs.google.com/document/d/1BcZAk28k7Uycr7iKKAVSiZ0MB9jDs9bODpdPZtYFH3Y/pub#h.
agz7rwlf8m6. Chimera detection involved de novo and reference-based steps, using the 
ChimeraSlayer gold database (http://drive5.com/uchime/uchime_download.html) derived from the 
ChimeraSlayer reference database (http://microbiomeutil.sourceforge.net/). OTUs were 
taxonomically classified using QIIME with SILVA reference database (version 123). An approximately-
maximum-likelihood phylogenetic tree was produced using the ‘ginsi’ alignment algorithm in 
MAFFT28, followed by FastTree29. 
 
Statistical analysis 
General linear models on Box-Cox transformed data were used to compare groups, accounting for 
the paired design of the prospective cohort, and adjusted using Bonferroni correction. We first 
compared the fecal metabolite concentrations and microbiota between HC and siblings of the CD 
patients. In the absence of significant difference, we removed the sibling group from further 
analysis. Multivariate statistical analysis was performed in R (version 3.4.0) using the packages 
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vegan, phyloseq and DESeq2. Samples were rarefied to 5,000 reads before calculating α diversity, 
measured as species richness and Shannon index. Microbial composition was assessed using non-
metric multidimensional scaling plots (NMDS) at genus and OTU level based on Bray-Curtis 
dissimilarity indices and unweighted UniFrac distances. The former considers bacterial taxon 
abundance, while the latter considers phylogenetic distances between bacterial taxa through 
presence/absence, regardless of proportional representation. Permutation ANOVA was applied 
using the vegan Adonis function on distance matrices (Bray-Curtis/ unweighted UniFrac) with data 
stratified by subject to allow for repeated sampling from UCD participants during follow-up. Local 
contribution to β-diversity (LCBD) analysis was performed to measure the contribution of each 
sample to the total OTU β diversity; samples with high LCBD represent samples that are markedly 
different from the average β diversity of all study samples. Differences in OTU abundances between 
groups were found using the DESeq2 method, with participant ID included as a variable in the input 
formula for paired data. For correlations Kendall rank correlation was used. Benjamini-Hochberg 
correction was applied to cases of multiple testing. Analysis using the Bioenv function in vegan 
produced subsets of OTUs whose Euclidean distance matrices correlate maximally with the Bray-
Curtis dissimilarity matrices derived from complete OTU tables, thus indicating major determinants 
of community structure. 
Random forest analysis used OTUs that significantly differed in abundance between HC versus both 
UCD and TCD patients inclusive. Models were generated using Log-proportional abundances via the 
randomForest R package, with 10,000 decision trees used per model. Model performance was 
assessed using the rf.significance function in the rfUtilities R package30 and ROC analysis using the 
ROCR R package31. 
 
Ethical considerations 
The study was approved by the West of Scotland Research Ethics Committee (Ref:11/WS/0006). All 
authors had access to the study data and reviewed and approved the final manuscript.
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RESULTS 
Participants 
141 children participated including, 45 TCD children on GFD, 20 UCD children on gluten containing 
diet, 19 siblings of 18 TCD children and 57 HC (Table 1). Thirty-three eligible participants (12 females) 
declined participation; 10 other (6 females) CD patients did not meet the inclusion criteria (i.e. 3 
unable to comprehend English, 1 had developmental delay, 1 child was in foster care, 4 had Type 1 
diabetes, 1 had congenital hypothyroidism). There was no difference in age (p=0.11) or gender 
(p=0.87) between participants and those who declined. All healthy children who expressed an 
interest participated in the study. 
All UCD children were recommended to follow a GFD. From the 20 UCD patients with 
baseline fecal samples, 13 (65%) provided follow-up samples at 6 and 12 months after GFD initiation 
(prospective cohort); 4 (20%) patients were lost at follow-up and 3 (15%) others provided paired 
samples at 12 months only but were subsequently removed to avoid bias in statistical analysis. There 
was no difference in age (p=0.27), gender (p=0.998) or BMI z-scores (p=0.63) as well as in α and β 
diversity of the baseline microbiota between the 13 patients with follow-up samples and the 7 
others who did not provide all samples. In total, 167 fecal samples were collected across all groups. 
After commencement of a GFD, tTG-IgA titer decreased in the UCD children (Table 1). The 
UCD group experienced more GI problems than TCD and HC. The mean PedsQL-GS score was also 
lower in TCD than HC, suggesting that TCD children had more GI symptoms than HC. In the UCD 
group, GI symptoms improved only 12 months post-diagnosis. 
 Thirty-eight of 45 TCD children (84%) had undetectable GIP, indicating at least recent 
compliance with GFD; the remaining 7 (16%) TCD children had detectable levels indicating either 
transgression from GFD recommendations or accidental exposure to gluten (Table 1). Compared to 
baseline, GIP concentration was almost 13 times lower at 6 months and 6 times lower at 12 months 
on GFD. At 6 and 12 months after recommendation to adhere to a GFD, 2 (15%) and 3 out of 13 
(23%) UCD patients had detectable GIP.  
 
Fecal microbiota profiling 
There was no difference in α-diversity between TCD, UCD and HC groups, neither at OTU nor genus 
level (Figure 1a & Supplementary Table 1). In contrast, 2.8% (p=0.025) and 2.5% (p=0.027) of the 
variation in OTU community structure (β-diversity) for the Bray-Curtis dissimilarity index and 
unweighted UniFrac distance analyses, respectively, were explained by participant grouping. TCD 
clustered separately to HC and tended to do so with respect to UCD (Supplementary Table 1), 
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suggesting a significant effect of GFD on microbiota structure. Similar findings were observed at 
genus level. Gender did not influence this effect. No separation in community structure was seen 
between the HC and UCD groups, suggesting an absence of profound dysbiosis at disease onset. 
LCBD analysis confirmed that the microbiota structure of TCD individuals differed from that of UCD 
and HC, with no difference seen between the latter 2 groups (Figure 1a).  
Using the Bioenv workflow, a subset of 13 OTUs maintained the group clustering, explaining 
92.3% of the variance described by the complete OTU dataset (Supplementary Table 2). When the 
Bioenv analysis was repeated for pairings of UCD vs TCD and HC vs TCD, separately, subsets of 14 
and 12 OTUs were retrieved, explaining 92.0% and 91.4% of the variance described by the complete 
datasets, respectively. Of note, 9 OTUs featured in both pairwise comparisons, suggesting their 
strong influence on the fecal microbiota structure of children with CD on a GFD. Compared to 
disease diagnosis, there was no difference in β-diversity of the 13 UCD children at 6 and 12 months 
after initiation of GFD (Figure 1b).  
 
Differential analysis in OTU abundance between new-onset, untreated CD and HC 
The UCD and HC groups were characterized by a total of 1,033 distinct OTUs. Thirty-one OTUs (3%) 
differed significantly between the 2 groups; all of which had a significantly lower abundance in UCD 
than HC (Figure 2). Of these 31 discriminatory OTUs, only the abundance of OTU_1054 Alistipes 
correlated positively with PedsQL-GS score; thus suggesting that the remaining 30 discriminatory 
OTUs were less likely to be explained by differences in GI symptoms between the 2 groups.  
 
Differential analysis in OTU abundance between patients on recommendation to a GFD with 
untreated CD or HC 
Next, we explored the effect GFD might have on the CD microbiota. First, we looked for differences 
in OTU abundances between UCD and TCD. Fifty-one of 1,082 OTUs (5%) differed significantly in 
abundance between the 2 groups (Figure 2 & Supplementary Table 3). Forty-eight OTUs (94%) had 
significantly higher abundance in TCD than UCD apart from OTU_31 Megamonas, OTU_143 
Ruminococcus 1, and OTU_135 Holdemanella. 
 Likewise, 29 of 1,082 OTUs (3%) had different abundance between HC and TCD. Almost half 
(n=13, 45%) were increased in TCD compared with HC (Figure 2). Of the 13 OTUs more abundant in 
TCD than HC, 10 (77%) were significantly higher in TCD than UCD too, suggesting that treatment with 
GFD influences these taxa independently of disease status. Of the 16 OTUs with lower relative 
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abundance in TCD than HC, OTU_31 Megamonas, OTU_143 Ruminococcus 1, and OTU_135 
Holdemanella had significantly lower abundance in TCD than UCD (Figure 2). Of note, these 3 OTUs 
were the only ones with lower abundance in TCD than UCD, strongly suggesting that their 
modulation is the consequence of treatment with GFD. 
 
A celiac disease-specific microbiota signature 
Irrespective of treatment with GFD, the relative abundance of 11 OTUs were consistently lower in 
children with CD than HC (Figure 2, Supplementary Table 3); hence composing a microbial signature 
specific to CD. This was visualized through NMDS analysis including only these 11 discriminant OTUs 
(Supplementary Figure 1). None of these 11 OTUs associated with disease duration [median, 3.1; 
IQR, 1.5: 7.3 yrs] in the TCD group. Using these 11 discriminatory OTUs, random forest classifier 
distinguished between HC and CD patients with an ‘out-of-bag’ error rate of 21.5%. This was 
significantly more effective than random classification (permutation ANOVA p<0.001 and 
AUC=0.789) (Figure 3). The 2 most influential OTUs were OTU_53 Clostridium sensu stricto 1 
followed by OTU_143 Ruminococcus. 
 
Discriminant analysis in OTU abundance in new-onset CD following recommendation to GFD  
In the prospective cohort of UCD patients followed-up at 6 and 12 months on GFD, fecal samples 
were characterized by a total of 835 OTUs; 31 (3.7%) and 12 (1.4%) of which differed significantly 6 
and 12 months after initiation of GFD, respectively (Figure 4). Compared to CD diagnosis, at both 6 
and 12 months on GFD, the relative abundance of 7 and 3 OTUs significantly decreased and 
increased, respectively. It is noteworthy that in this prospective cohort the mean effect size of GFD 
on OTU abundance (Figure 4) was more pronounced than the magnitude of OTU abundance 
difference between TCD and UCD (Figure 2).    
 
Effect of dietary nutrients and food groups on the gut microbiota of CD 
The effect dietary modifications, during treatment with GFD, might have on microbiota was explored 
using stepwise data analysis. First, we correlated the intake of macronutrients (e.g. carbohydrates) 
and food groups (e.g. dairy portions/day) with the abundance of all OTUs characterizing the 
microbiota of HC (Supplementary Figure 2 & Supplementary Figure 3). Significantly related OTUs 
were subsequently cross-referenced with the discriminant OTUs for comparisons between UCD or 
HC with TCD, as well as in the subset of UCD patients with paired data at 6 and 12 months. We 
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applied this analysis workflow as, despite assessing the dietary intake of our CD patients with the 
FFQ, complete nutritional composition of gluten-free products is currently unavailable and therefore 
the outcome of dietary assessment, in this group, would have been incomplete and findings 
misleading.   
Of the 200 OTUs which associated with either the macronutrient or food group intake of HC, 
39 OTUs were differentially abundant between UCD and TCD children (Figure 2) suggesting that 
differences in the abundance of 39 of the 51 (76%) discriminatory OTUs between UCD and TCD are 
likely to be explained by changes in dietary nutrient intake after GFD recommendation. Likewise, 23 
of the 200 OTUs were significantly differentially abundant between HC and TCD children (Figure 2). 
Therefore, differences in abundance of 23 of the 29 (79%) OTUs that discriminated between HC and 
TCD are likely to be explained by changes in dietary intake after initiation of GFD.  
In the prospective cohort, from the 31 and 12 OTUs whose relative abundance changed at 6 
and 12 months of treatment with GFD, 29 (94%) and 11 (82%) correlated with macronutrient or food 
group intake in HC (Figure 4), further supporting the hypothesis that the gut microbiota of treated 
CD patients differs to HC predominantly as the result of dietary modification during GFD.  
 
Differential analysis in OTU abundance between patients with and without recent consumption of 
gluten  
In pooled analysis (cross-sectional and prospective cohorts together), 12 (17%) children with 
recommended adherence to a GFD had detectable and 59 (83%) undetectable GIP. When we looked 
for differences in OTU abundance between these 2 groups, 89 OTUs differed (Supplementary Figure 
4). Among these, all but 2 (OTU_99 Senegalimassilia and OTU_239 Clostridiales vadinBB60 group) 
OTUs were higher in children with undetectable fecal GIP.  
For a few discriminatory OTUs between UCD and/or HC with TCD the direction of their 
change in abundance differed to that of those OTUs which discriminated between patients with and 
without recent gluten consumption. 19 out of the 87 OTUs (22%) with higher abundance in children 
without recent gluten ingestion were significantly increased in TCD compared with UCD, with 8 of 
them (9%) also significantly increased in TCD over HC (Supplementary Figure 4). Similarly, 1 of the 2 
OTUs (50%) with lower abundance in children without recent gluten ingestion was also significantly 
lower in TCD than in HC. 
 
Comparison in microbiota between treated patients with CD and their unaffected siblings 
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There was no difference in the microbiota structure (β-diversity) of the TCD patients and their 
unaffected siblings (Supplementary Table 1). The microbiota structure of the unaffected siblings did 
not differ to HC either. Fifty-six of 964 OTUs (6%) were differentially abundant between TCD and 
their unaffected siblings, with 36 (64%) significantly decreased in the TCD group (Supplementary 
Table 5).   
 
Diet-related microbiota metabolites 
There was no difference between the unaffected siblings of TCD children and HC in all bacterial 
metabolites assayed, water content and pH in feces (Table 2). No difference was found also in fecal 
water content and the absolute concentration of SCFA/BCFA among the UCD, TCD and HC. However, 
the relative abundance (%) of acetic acid was higher, and that of butyric and valeric acids were lower 
in TCD than HC (Figure 5a). 
In the prospective group of UCD patients the absolute concentrations of butyric acid 
(p=0.053) and the 2 BCFA (isovaleric acid, p=0.052, isobutyric acid, p=0.063) non-significantly 
decreased after GFD initiation (Table 2). The effect of GFD on SCFA production was reflected also in 
their proportional profile (Figure 5b). Compared with disease diagnosis, the relative abundance of 
acetic acid increased and the relative abundances of propionic, butyric and valeric acids decreased at 
6 and/or 12 months on GFD, mirroring the observations in the cross-sectional cohort and between 
the TCD children and HC or UCD. 
Samples from TCD children had lower ammonia concentration than HC or UCD, and patients 
with UCD had significantly less free sulfide than HC (Table 2). Mean fecal L-lactic acid concentration 
was significantly lower in UCD than TCD and HC, but its D-isomer was higher in UCD than TCD. 
During the follow-up of the 13 UCD children, a non-significant (p=0.067) decrease in ammonia levels 
and a corresponding increase in free sulfide (p=0.074) and L-lactate (p=0.087) concentrations were 
observed. 
There was no difference in bacterial metabolites, except for fecal ammonia which was 
significantly lower in patients who had undetectable GIP than those who had consumed gluten 
(Supplementary Table 6). 
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DISCUSSION 
It is still unclear the extent to which an altered microbiota observed in previous research8-17 is 
involved in CD pathogenesis or if these are secondary effects of disease pathology, including 
increased epithelial cell turnover and nutrient malabsorption. Following diagnosis, adherence to GFD 
may associate with a decreased intake of non-digestible carbohydrates from cereals, thus affecting 
fiber fermenting species and colonic production of SCFA32. This is important as CD patients may be 
unable to compensate for decreased fiber intake from gluten-containing foods by increasing its 
intake from other sources, including fruits and vegetables. Here, by performing a data-rich study we 
tried to discern which microbial signals in patients with new-onset and treated CD are potentially 
involved in disease pathogenesis and which are secondary disease effects, including from treatment.   
Even though we identified differences in the abundance of a few species between 
treatment-naïve UCD patients and HC, the profound microbial dysbiosis noted in Crohn’s disease 
was not observed, at least using crude diversity indices 18. Instead, significant effects were observed 
in TCD patients after recommendation to a GFD, confirming our a priori hypothesis. More 
importantly, we identified three major groups of bacterial taxa (Figure 2); one group which is CD-
specific and non-responsive to treatment with GFD; a second group which is associated with new-
onset CD but which is also treatment responsive; and a third one which is treatment dependent but 
does not differentiate between disease and the health state. Of these, the first cluster represents 
the microbial signature of CD which can distinguish children with from those without CD with a 
reasonably high likelihood, as demonstrated using machine learning algorithms. The magnitude of 
microbial alterations observed here are similar to other non-communicable diseases, in which the 
microbiota has been implicated in their underlying pathogenesis, such as type 1 diabetes 33. 
Although in the second group several other bacteria were different between UCD and the 
HC, these discriminatory microbial signals vanished following treatment with GFD. These represent 
bacteria which responded to recovery of gut pathology following treatment with GFD, or bacteria 
whose underlying role in CD cause and treatment might be important. The role of these taxa, the 
majority of which belong to Bacteroidetes warrants further research. Using denaturing gradient gel 
electrophoresis with group-specific primers Sánchez showed also that Bacteroides diversity was 
higher in duodenal biopsies from controls than in samples from patients with active and treated 
CD15.  
The third and largest group should almost certainly represent microbial noise attributed to 
dietary modification during treatment with GFD and amelioration of disease activity. This 
speculation is supported by the fact that several differential OTUs between the TCD with the UCD 
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children or HC overlapped; most of these discriminatory species were associated with participants’ 
diet, as well as by the observation that in patients on GFD almost 100 OTUs differed between 
patients with positive and negative gluten contents in their feces. As a prime example of these 
effects, avoidance of wheat products likely explains the decrease of Megamonas in TCD patients34 
and the same may apply for the fiber fermenters Coprococcus, Ruminococcus and Anaerostipes, and 
Bifidobacterium. The reduction in Bifidobacterium in CD is in accordance with previous research 
using molecular fingerprinting techniques17 and quantitative PCR9. Of note, 41% of the genera which 
were influenced by GFD in the current study were also influenced in healthy adults who adhered to 
other dietary interventions which were gluten free and low in fiber (Supplementary Figure 5) in 
previous research25. This further corroborates our conclusions that to a large extent OTUs which are 
altered in TCD are the result of GFD and low fiber intake. Changes in the abundance of butyric acid 
producers paralleled a decrease in butyric acid levels and its proportional abundance in patients on 
GFD. This finding confirms previous observations12, but here we provide evidence that this is a 
secondary effect and not primary disease defect. The concentration of ammonia and BCFA was 
lower in patients on GFD; both in the cross-sectional and prospective cohorts. This likely indicates 
reduction in protein intake or lower epithelial cell shedding, with amelioration of intestinal 
inflammation, both resulting in less protein reaching the colon and being fermented. The reason 
behind the low concentration of free sulfide at disease diagnosis is unclear but in conjunction with 
the significantly reduced abundance of Methanobrevibacter, a methane producer, suggests an 
altered hydrogen metabolism in newly diagnosed CD. Hydrogen sulfide has been implicated in 
various processes of gut function including motility, epithelial secretion and protection from 
inflammation35.   
Findings from the prospective cohort corroborated the results of the cross-sectional group 
analysis although often different species were affected by GFD between the two cohorts, 
highlighting substantial variation in inter-individual responses. The observation that almost three 
times fewer species were affected after 12 compared with 6 months diagnosis indicates either 
better adaptation of CD patients to GFD and broader food choices to compensate for gluten-
containing food with time or, most likely and supported by the change in GIP levels between these 
periods, loss of strict compliance to GFD in some patients.  
There are significant implications for future research and clinical practice arising from the 
findings of this study. The role of CD-associated microbiota in disease pathogenesis, including those 
organisms which respond to GFD, needs to be unraveled in mechanistic research. The fact that the 
CD microbial signature we observed persisted in patients on GFD and was independent of disease 
duration suggests that the effects on these 11 OTUs are unrelated to bacterial fermentation of the 
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luminal glycocalyx and other gastrointestinal secretions or mediators of the innate immune system. 
It is therefore possible that these bacterial species are important modifiers of risk of CD onset, 
particularly in individuals who are genetically susceptible to developing the illness. In previous 
research, healthy exclusively breastfed infants who were carriers of the HLA-DQ2 haplotype and also 
had family history of CD, had less Bifidobacterium36. Provided that the majority of patients with CD 
are carriers of the HLA-DQ2 haplotype the observation of a lower Bifidobacterium abundance 
reported in the current and previous study36 suggests that genetic factors which impede the early 
colonization of the gut with species beneficial for human health, may potentiate the risk of 
development of CD; this effect extends beyond disease diagnosis and remains independent of GFD 
treatment.  
The role of Bifidobacterium in the underlying microbial origins of CD pathogenesis has 
received extensive attention within mechanistic research. Inoculation of peripheral blood 
mononuclear cells with feces from active and asymptomatic CD patients increased TNF-α production 
and CD86 expression, while decreased IL-10 cytokine production and CD4 expression compared with 
samples from HC but specific Bifidobacterium strains suppressed this Th1 pro-inflammatory milieu, 
characteristic of CD 37. In a subsequent study of the same group, addition of Bifidobacterium strains 
changed the gliadin-derived peptide pattern and attenuated production of TNF-α and IL-1β and 
expression of NF-κB and chemokine CXCR3 receptor from Caco-2 cells exposed to gliadin digestions 
38. These in-vitro data were replicated in gliadin-induced enteropathy murine models sensitized with 
interferon-γ where Bifidobacterium longum CECT 7347 attenuated the production of TNF-α and the 
CD4 mediated immune response and increased the tissue mRNA levels of NFκB and IL-10 39.  
The exact mechanism by which Bifidobacteria may exhibit immune-modulating properties is 
not yet clear but it has been demonstrated that Bifidobacterium longum NCC2705 produces a serine 
protease inhibitor which attenuates gliadin-induced immunopathology and impacts on intestinal 
microbial composition in the NOD/DQ8 mouse model of gluten sensitivity40. In one of the few clinical 
trials available, administration of Bifidobacterium infantis decreased Paneth cells and expression of 
α-defensin-5 in duodenal biopsy of patients with active CD41; an effect which was associated with 
symptom improvement but which did not modify abnormal intestinal permeability42.  
Very few other species identified here as disease specific biomarkers have been studied in 
the context of CD pathogenesis. Commensal Clostridia belonging to clusters IV and XIVa are 
important inducers of Tregs in the colon43. It is therefore possible that the highly discriminant 
OTU_53 belonging to an unknown Clostridium is less abundant in CD thus influencing the induction 
of Tregs required for maintaining immune homeostasis. It has also been shown that bacteria could 
potentially reduce gluten immunogenicity by producing enzymes that effectively cleave proteolytic-
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resistant sequences in gluten peptides which activate Th1 response44. Pseudomonas aeruginosa, 
isolated from the duodenum of CD patients, produces, through its elastase activity, a multitude of 
peptides that activate gluten-specific T cells in HLA-DQ2 CD patients but conversely, Lactobacillus 
spp from healthy subjects, degrade such modified peptides and decrease their immunogenic 
potential45. 
Future research should explore the role of the disease-specific species identified here in 
disease pathogenesis. Such studies may include in-vitro experiments with candidate species and 
immune cell co-cultures triggered by gliadin epitopes and dietary interventions aiming to change 
their abundance in the gut coupled with measurements of disease outcomes13. The ability of 
microbiota signatures of unaffected siblings to predict risk of CD onset alongside other 
environmental factors is important to study and in a similar way to ongoing large cohort studies in 
Crohn’s disease46. 
Irrespective of their primary role in CD pathogenesis, the disease-specific microbial signature 
identified here might be used as another adjutant, non-invasive biomarker to screen for CD. The 
observation that the abundance of fiber fermenters or cross-feeders and production of butyric acid 
diminish in patients on GFD has implications for the dietary management of this population. Dietary 
fiber intake in the westernized diet is low and adherence to GFD with low consumption of cereals 
may decrease patient intake even further. It is therefore important for colonic health and gut 
motility to promote intake of non-gluten containing sources of fiber in this population and routinely 
fortify gluten-free products with a broad variety of fibers (e.g. pectin, ispaghula).  
Limitations of the current study include the modest sample size of the prospective group. 
Although the mean effect size of microbial changes were more pronounced than the cross-sectional 
group, we may have been underpowered to identify smaller size differences. Some patients from 
the UCD group were lost at follow-up or their measurements were excluded. However, this group of 
patients did not differ in characteristics and microbiota features from patients who were retained in 
the analysis. Also, CD is a condition of the small bowel; hence the role of the fecal microbiota may be 
considered less relevant to its pathogenesis. While this is a fair argument to propose, it is possible 
that events in the large bowel influence disease pathogenesis upstream along the GI tract, as is 
perhaps the case in Crohn’s disease where colonic microbiota changes can be seen in patients with 
disease affecting their small intestine. It is also possible that several fecal microbes are markers of 
the small bowel resident community. Collado et al previously showed that similar bacteria were 
related to CD in both fecal and duodenal biopsies47; but further research is required to clarify the 
role of each of these gut niches and in the mucosal adherent microbiota as suggested9, 48. In HC we 
did not have ethical permission to screen for CD. The fact though that none of the siblings of the CD 
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patients screened positive for CD infers that the proportion of HC with undiagnosed CD would have 
been small and unlikely to have influenced the main results presented here.   
In conclusion, we identified a set of bacteria which may comprise another important 
environmental factor in the pathogenesis of CD and which warrant further research, but also 
demonstrated that several alterations in the microbiota of patients with established CD are likely to 
be secondary effects of disease treatment. The suppression of butyric acid production and fiber 
fermenters is likely a biomarker of diminished consumption of fermentable carbohydrate and may 
suggest a need for the development of fiber-enriched gluten-free products and interventions with 
prebiotics.    
 
 
FIGURE & TABLE LEGENDS 
 
Figure 1: α and β-diversity for the cross-sectional (a) and prospective (b) cohort 
HC: Healthy controls, UCD: newly-diagnosed celiac disease, TCD: patients with celiac disease on 
gluten-free diet; NMDS: non-metric multidimensional scaling 
 
 
Figure 2: Statistically significant differences (log2-fold change) in relative abundance of OTUs 
between groups and correlations between these discriminatory OTUs with dietary nutrients and 
food groups  
HC: Healthy controls, UCD: newly-diagnosed celiac disease, TCD: patients with celiac disease on 
gluten-free diet; A negative log2-fold change represents a lower abundance in the second of the 
two-group comparison 
 
Figure 3: Most influential OTUs, among the 11 disease-specific, in predicting disease or health status 
with associated receivers operating curves and area under the curve 
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Figure 4: Statistically significant differences (log2-fold change) in relative abundance of OTUs 
between follow-up timepoints and correlations between these discriminatory OTUs with dietary 
nutrients and food groups  
UCD: newly-diagnosed celiac disease; GFD 6 and 12 mos: UCD patients on gluten-free diet for 6 and 
12 months, respectively.   
 
Figure 5: Relative proportion (%) of short-chain fatty acids 
C2: acetic, C3: propionic, C4: butyric, C5: valeric, iC4: isobutyric, iC5: isovaleric acids; HC: Healthy 
controls, UCD: newly-diagnosed celiac disease, TCD: patients with celiac disease on gluten-free diet; 
6 and 12 mos: UCD patients on gluten-free diet for 6 and 12 months, respectively.   
 
 
Table 1: Participants characteristics of the cross-sectional study and prospective cohort 
 
Table 2: Fecal characteristics and microbiota metabolites in the cross-sectional study and 
prospective cohort 
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Table 1: Participants characteristics of the cross-sectional study and prospective cohort  
 
Cross-sectional study Prospective study 
 
HC (57) Siblings (19) UCD (20) TCD (45) Diagnosis (13) 6 months GFD (13) 12 months GFD (13) 
Age (y) 7.8 (0.41) 9.1 (0.76) 10.1 (0.70)
a
 9.3 (0.47) 9.5 (0.87) 10.1 (0.87) 10.6 (0.86) 
Gender (M/F) 27/30 8/11 10/10 20/25 6/7 6/7 6/7 
Weight (Kg) 29.1 (1.6) 33.7 (3.8) 33.7 (2.9) 32.3 (1.7) 30.5 (3.1)
b
 32.5 (3.3)
c
 34.8 (3.5) 
Height z-score 0.29 (0.15) 0.43 (0.28) -0.16 (0.22) 0.06 (0.16) -0.19 (0.30) -0.15 (0.28) -0.20 (0.27) 
<-2SD [n(%)] 1 (1.8) 0 (0) 2 (10.0) 0 (0) 2 (15.4) 1 (7.7) 1 (7.7) 
BMI (Kg/m
2
) 16.8 (0.34) 17.5 (0.62) 17.1 (0.58) 17.4 (0.38) 16.5 (0.67)
d
 16.6 (0.71) 17.1 (0.79) 
BMI z-score 0.06 (0.15) 0.24 (0.23) -0.23 (0.25) 0.18 (0.17) -0.40 (0.34) -0.45 (0.33) -0.31 (0.33) 
<-2 SD [n(%)] 1 (1.8) 0 (0) 2 (10.0) 0 (0) 2 (15.4) 2 (15.4) 2 (15.4) 
>2 SD [n(%)] 4 (7.0) 2 (10.5) 0 (0) 3 (6.7) 0 (0) 0 (0) 0 (0) 
tTG (U/mL) - - 64.8 (13.3) [9] 7.9 (3.0)
e
 [2] 68.5 (19.6)
b
 [7] 9.8 (3.3)
f
 [4] 7.7 (2.0) [4] 
<7 [n(%)] - - 1 (9.1) 34 (79.1) 1 (16.7) 3 (33.3) 6 (66.7) 
≥7 [n(%)] - - 10 (90.9) 9 (20.9) 5 (83.3) 6 (66.7) 3 (33.3) 
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GIP (μg/g) - - 3.5 (0.6) [1] 0.25 (0.06)
e
  2.95 (0.76)
b
 [1] 0.22 (0.06) 0.49 (0.23) 
<0.156 [n(%)] - - 1 (5.3) 38 (84.4) 0 (0) 11 (84.6) 10 (76.9) 
≥0.156 [n(%)] - - 18 (94.7) 7 (15.6) 12 (100) 2 (15.4) 3 (23.1) 
PedsQL-GS score 91.4 (1.7) [1] 88.2 (2.9) 57.1 (4.8)
g
 77.5 (2.7)
h
 58.3 (6.2)
i
 67.1 (5.3) 73.6 (6.4) 
 
Values expressed as mean (SEM); GLM for UCD, TCD & HC in the cross-sectional study and GLM accounted for paired design in the prospective study; Box-
Cox transformation with optimal λ in all but BMI z-score; pairwise comparison with Bonferroni correction; the number of missing data is shown in brackets; 
a
: p-value= 0.017 compared to HC; 
b
: p<0.0001 compared to 6 months GFD & 12 months GFD; 
c
: p< 0.0001 compared to 12 months GFD; 
d
: p=0.018 
compared to 12 months GFD; 
e
: p< 0.0001 compared to UCD; 
f
: p= 0.029 compared to 12 months GFD; 
g
: p< 0.0001 compared to HC; 
h
: p< 0.0001 compared 
to UCD and HC;
 i
: p= 0.009 compared to 12 months GFD; *p: for all-group (except for siblings) comparison 
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Table 2: Fecal characteristics and microbiota metabolites in the cross-sectional study and prospective cohort 
 
Cross-sectional study Prospective study 
 
HC (57) Siblings (19) UCD (20) TCD (45) Diagnosis (13) 6 months GFD (13) 12 months GFD (13) 
Faecal pH  6.9 (0.08) 6.9 (0.15) [1] 6.7 (0.3) 7.1 (0.1) [2] 6.4 (0.46) 7.2 (0.18) [1] 6.8 (0.16) [1] 
Faecal water content (%)  67.8 (0.7) 65.5 (1.6) 66.3 (1.7) 69.2 (1.2) [2] 67.6 (0.46) 65.8 (1.1) 69.1 (2.0) 
Ammonia (*10
-4 
mg/g) 11.5 (0.8) 11.4 (1.4) 19.6 (8.2) 7.8 (0.8)
a
 [2] 11.2 (0.96) 8.0 (1.2) 11.1 (1.6) [2] 
Free sulphide (μmol/g) 0.13 (0.02) [2] 0.13 (0.03) 0.06 (0.01)
b
 [2] 0.10 (0.01) [4] 0.03 (0.01) [1] 0.05 (0.01) 0.09 (0.02) 
Total sulphide (μmol/g) 0.83 (0.10) 1.15 (0.17) 0.83 (0.13) [2] 1.03 (0.11) [3] 0.87 (0.17) [1] 0.72 (0.13) 0.57 (0.11) 
L-lactic acid (μg/g)   126.8 (41.3) 114.0 (11.1) [2] 60.1 (14.0)
c, d
  [1] 100.8 (11.6) [7] 55.3 (16.6) 67.6 (10.9) 81.5 (11.2) 
D-lactic acid (μg/g)  92.5 (18.4) 60.4 (6.4) [2] 119.1 (23.6) [1]  62.5 (4.1)
e
 [7] 130.2 (33.9)  116.9 (16.9)  123.2 (15.6)  
Total lactic acid (μg/g) 219.3 (59.4) 174.4 (11.6) [2] 179.2 (29.0) [1] 163.3 (13.6) [7] 185.5 (38.6) 184.4 (17.5) 204.7 (18.0) 
Acetic acid (μmol/g) 128.2 (5.2) 117.9 (8.6) 119.9 (10.0) [1] 124.6 (6.9) [2] 121.9 (13.8) 124.0 (12.6) 116.6 (11.1) 
Propionic acid (μmol/g) 25.8 (1.6) 23.1 (3.0) 23.2 (2.7) [1] 23.1 (2.1) [2] 26.7 (3.5) 22.0 (2.9) 23.6 (3.0) 
Butyric acid (μmol/g) 24.4 (1.5) 21.9 (2.8) 23.2 (3.3) [1] 21.0 (2.5) [2] 26.7 (4.4) 19.8 (5.4) 20.5 (2.5) 
Valeric acid (μmol/g) 3.1 (0.18) 2.9 (0.31) 3.0 (0.37) [1] 2.5 (0.24) [2] 3.2 (0.51) 2.3 (0.37) 2.4 (0.33) 
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Isobutyric acid (μmol/g) 3.6 (0.22) 3.5 (0.35) 3.8 (0.46) [1] 3.0 (0.25) [2] 4.0 (0.64) 3.1 (0.37) 2.7 (0.35) 
Isovaleric acid (μmol/g) 3.6 (0.23) 3.5 (0.32) 3.9 (0.48) [1] 3.1 (0.28) [2] 4.1 (0.66) 3.1 (0.37) 2.6 (0.33) 
Total SCFA (μmol/g) 188.6 (7.9) 172.8 (14.6) 176.9 (15.9) 177.3 (11.4) 186.6 (21.7) 174.4 (21.3) 168.5 (14.9) 
 
Values expressed as mean (SEM); GLM for UCD, TCD & HC in the cross-sectional study and GLM accounted for paired data in the prospective study; Box-Cox 
transformation with optimal λ; pairwise comparison, Bonferroni method; the number of missing data is shown in brackets; metabolites are measured per 
wet matter; 
a
: p=0.001 compared to HC & UCD; 
b
: p= 0.009 compared to HC; 
c
: p= 0.012 compared to HC; 
d
: p= 0.003 compared to TCD; 
e
: p=0.037 compared 
to UCD; 
f
: p= 0.009 compared to HC; 
g
: p= 0.003 compared to diagnosis; 
h
: p=0.017 compared to HC; 
i
: p= 0.013 compared to diagnosis; 
j
: p=0.045 compared 
to HC; 
k
: p= 0.008 compared to diagnosis; 
l
: p= 0.014 compared to diagnosis; *: for all groups comparison 
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OTU_60_Genus_Bacteroides
OTU_78_Genus_Ruminiclostridium 5
OTU_120_Genus_Lachnospiraceae UCG-005
OTU_197_Genus_Ruminococcaceae UCG-005
OTU_28_Genus_Bacteroides
OTU_1002_Genus_Lachnospira
OTU_88_Genus_Bacteroides
OTU_752_Genus_Subdoligranulum
OTU_1049_Genus_Lachnoclostridium
OTU_125_Genus_Parabacteroides
OTU_278_Genus_Akkermansia
OTU_186_Order_Gastranaerophilales
OTU_174_Genus_Catenibacterium
OTU_302_Genus_Eisenbergiella
OTU_270_Genus_Butyricimonas
OTU_317_Genus_Lachnospiraceae NK4A136 group
OTU_248_Genus_Clostridium sensu stricto 1
OTU_34_Genus_Bacteroides
OTU_259_Genus_Erysipelatoclostridium
OTU_1036_Class_Bacteroidetes VC2.1 Bac22
OTU_1104_Genus_Akkermansia
OTU_154_Genus_Odoribacter
OTU_77_Genus_Lachnoclostridium
OTU_136_Genus_[Eubacterium] coprostanoligenes group
OTU_139_Genus_Bilophila
OTU_46_Genus_Incertae Sedis
OTU_63_Genus_Blautia
OTU_73_Genus_Bacteroides
OTU_235_Family_Lachnospiraceae
OTU_282_Family_Christensenellaceae
OTU_448_Genus_Ruminiclostridium 5
OTU_343_Family_Christensenellaceae
OTU_98_Family_Ruminococcaceae
OTU_176_Genus_Lachnoclostridium
OTU_134_Genus_Ruminiclostridium 5
OTU_355_Genus_Lachnoclostridium
OTU_245_Genus_Christensenellaceae R-7 group
OTU_979_Genus_Bifidobacterium
OTU_908_Genus_Anaerostipes
OTU_135_Genus_Holdemanella
OTU_244_Genus_Ruminococcus 1
OTU_114_Genus_Coprococcus 2
OTU_923_Genus_Marvinbryantia
OTU_168_Genus_Alistipes
OTU_190_Genus_Alistipes
OTU_3_Genus_Akkermansia
OTU_111_Genus_Blautia
OTU_572_Genus_Family XIII AD3011 group
OTU_65_Genus_Bacteroides
OTU_51_Genus_Ruminococcaceae UCG-014
OTU_109_Genus_Ruminococcus 2
OTU_49_Genus_Alistipes
OTU_868_Genus_Bacteroides
OTU_1_Genus_Prevotella 9
OTU_230_Genus_Bacteroides
OTU_226_Genus_[Eubacterium] oxidoreducens group
OTU_1054_Genus_Alistipes
OTU_112_Class_Bacteroidetes VC2.1 Bac22
OTU_45_Genus_Parabacteroides
OTU_146_Genus_Slackia
OTU_895_Genus_Barnesiella
OTU_101_Genus_Anaerotruncus
OTU_143_Genus_Ruminococcus 1
OTU_31_Genus_Megamonas
OTU_776_Genus_Bifidobacterium
OTU_84_Genus_Enterorhabdus
OTU_336_Genus_Holdemanella
OTU_537_Genus_Dialister
OTU_53_Genus_Clostridium sensu stricto 1
OTU_70_Genus_Ruminococcaceae UCG-014
OTU_42_Genus_Methanobrevibacter
OTU_99_Genus_Senegalimassilia
OTU_62_Genus_Ruminococcaceae UCG-014
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 What you need to know: 
Background and Context: It is not clear whether alterations in the intestinal microbiota of 
children with celiac disease cause the disease or are a result of disease and/or its treatment 
with gluten-free diet (GFD). 
 
New Findings: Although several alterations in the intestinal microbiota of children with 
established celiac disease appear to be effects of a GFD, there are specific bacteria that are 
distinct biomarkers of celiac disease.  
 
Limitations: It is not clear whether the microbes identified contribute to pathogenesis of 
celiac disease or are the result of it. 
 
Impact: The GFD alters the intestinal microbiota, but in patients with celiac disease, there 
are additional differences, compared with healthy children. 
 
 
 
Lay Summary: Children with celiac disease have differences in composition of intestinal 
microbes compared to healthy children. Some of these differences are caused by a gluten-free 
diet, but studies are needed to determine whether the other changes are a cause or a result of 
celiac disease. 
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Supplementary Figure 1: Non-metric multidimensional scaling of the microbial community formed by 
only the 11 discriminant OTUs between children with celiac disease and healthy controls 
 
Supplementary Figure 2: All significant correlations between the abundances of OTUs from the 
microbiota of the healthy controls with their dietary nutrient intake 
%TDEI: %Total dietary energy intake; MUFA: Mono-unsaturated fatty acids; NMES: Non-milk extrinsic 
sugars; NSP: Non-starch polysaccharides; DRV: Dietary Reference Value; RNI: Reference Nutrient Intake; 
PUFA: Polyunsaturated fatty acids; SFA: Saturated fatty acids  
 
Supplementary Figure 3: All significant correlations between the abundances of OTUs from the 
microbiota of the healthy controls with the intake of food groups  
 
Supplementary Figure 4: Differential OTUs between patients, on gluten-free diet recommendation with 
positive and negative fecal gluten immunogenic peptide. Bar color indicates significant OTUs with 
significant difference between 2 groups 
 
Supplementary Figure 5: Changes in genera during gluten free diet (GFD) in children with celiac disease 
of the current study and their overlap with genera which changed following treatment with exclusive 
enteral nutrition (EEN) or a new dietary therapy for Crohn’s disease (CD-TREAT) in healthy adults in 
previous research
25
 
Red color indicates increase and blue color decrease in relative abundance    
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Supplementary Table 1: PERMANOVA analysis using Bray-Curtis and unweighted UniFrac metrics at OTU 
and genus level 
 
Supplementary Table 2: Bioenv selected OTU that explain part [(a) 92.3% in UCD, TCD and HC, (b) 92% 
in UCD and TCD, (c) 91.4% in HC and TCD children] of the variance in microbiota structure described by 
the full OTU dataset 
 
Supplementary Table 3: OTUs with significantly different relative abundance in fecal samples of UCD, 
TCD and HC 
 
Supplementary Table 4: OTUs with significantly different relative abundance in fecal samples of (a) 
paired data from 13 CD children at diagnosis and at six and 12 months after the initiation of GFD, and (b) 
from cross-sectional data from UCD patients (n=20) and TCD patients (n=45) 
 
Supplementary Table 5: OTUs with significantly different relative abundance in fecal samples of 18 TCD 
children and their unaffected 19 siblings 
 
Supplementary Table 6: Fecal metabolites in celiac disease children with or without recent ingestion of 
gluten 
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OTU_26_Genus_Coprococcus 3
OTU_19_Genus_Ruminococcaceae UCG-002
OTU_15_Genus_Dorea
OTU_68_Genus_Ruminococcaceae UCG-005
OTU_96_Genus_Ruminococcus 1
OTU_115_Genus_Parasutterella
OTU_130_Genus_Christensenellaceae R-7 group
OTU_65_Genus_Bacteroides
OTU_129_Genus_Eggerthella
OTU_47_Genus_[Eubacterium] coprostanoligenes group
OTU_148_Genus_Ruminococcaceae UCG-013
OTU_3_Genus_Akkermansia
OTU_868_Genus_Bacteroides
OTU_118_Genus_Terrisporobacter
OTU_55_Genus_[Eubacterium] coprostanoligenes group
OTU_95_Genus_Ruminiclostridium
OTU_42_Genus_Methanobrevibacter
OTU_56_Genus_Ruminiclostridium 5
OTU_143_Genus_Ruminococcus 1
OTU_83_Genus_Alistipes
OTU_67_Genus_Christensenellaceae R-7 group
OTU_70_Genus_Ruminococcaceae UCG-014
OTU_36_Genus_Streptococcus
OTU_76_Genus_Coprococcus 1
OTU_30_Genus_Intestinibacter
OTU_537_Genus_Dialister
OTU_100_Genus_Ruminococcaceae UCG-004
OTU_776_Genus_Bifidobacterium
OTU_119_Genus_Family XIII AD3011 group
OTU_53_Genus_Clostridium sensu stricto 1
OTU_151_Genus_Turicibacter
OTU_513_Genus_Blautia
OTU_35_Genus_Blautia
OTU_108_Family_Coriobacteriaceae
OTU_94_Genus_Christensenellaceae R-7 group
OTU_24_Genus_Lachnoclostridium
OTU_113_Genus_Clostridium sensu stricto 1
OTU_16_Genus_Blautia
OTU_99_Genus_Senegalimassilia
OTU_41_Genus_Intestinibacter
OTU_413_Genus_[Ruminococcus] gauvreauii group
OTU_8_Genus_Ruminococcus 2
OTU_132_Genus_Gordonibacter
OTU_12_Genus_Subdoligranulum
OTU_87_Family_Ruminococcaceae
OTU_568_Genus_Bifidobacterium
OTU_893_Genus_[Eubacterium] hallii group
OTU_5_Genus_Phascolarctobacterium
OTU_13_Genus_Anaerostipes
OTU_761_Genus_Bifidobacterium
OTU_61_Genus_Roseburia
OTU_752_Genus_Subdoligranulum
OTU_29_Genus_Christensenellaceae R-7 group
OTU_71_Genus_Phascolarctobacterium
OTU_51_Genus_Ruminococcaceae UCG-014
OTU_75_Genus_Bacteroides
OTU_895_Genus_Barnesiella
OTU_91_Genus_Blautia
OTU_63_Genus_Blautia
OTU_139_Genus_Bilophila
OTU_52_Genus_Ruminococcus 1
OTU_110_Genus_Ruminococcus 1
OTU_48_Genus_Lachnospiraceae UCG-008
OTU_60_Genus_Bacteroides
OTU_57_Genus_Lachnospira
OTU_622_Genus_Lachnospiraceae UCG-001
OTU_104_Genus_Incertae Sedis
OTU_123_Genus_Haemophilus
OTU_43_Genus_Veillonella
OTU_23_Genus_Lachnospiraceae NK4A136 group
OTU_122_Genus_Ruminiclostridium 9
OTU_6_Genus_Dialister
OTU_154_Genus_Odoribacter
OTU_88_Genus_Bacteroides
OTU_34_Genus_Bacteroides
OTU_9_Genus_Pseudobutyrivibrio
OTU_44_Genus_Ruminococcaceae UCG-005
OTU_258_Family_Lachnospiraceae
OTU_14_Genus_Subdoligranulum
OTU_1049_Genus_Lachnoclostridium
OTU_21_Genus_Coprococcus 2
OTU_79_Genus_Ruminococcaceae NK4A214 group
OTU_10_Genus_Faecalibacterium
OTU_112_Class_Bacteroidetes VC2.1 Bac22
OTU_89_Genus_Faecalibacterium
OTU_92_Genus_Lachnospiraceae FCS020 group
OTU_54_Genus_Lachnoclostridium
OTU_141_Family_Lachnospiraceae
OTU_98_Family_Ruminococcaceae
OTU_28_Genus_Bacteroides
OTU_302_Genus_Eisenbergiella
OTU_20_Genus_Bacteroides
OTU_86_Genus_Alistipes
OTU_881_Genus_Faecalibacterium
OTU_655_Genus_Bacteroides
OTU_298_Genus_Lachnoclostridium
OTU_66_Genus_Ruminococcaceae UCG-005
OTU_49_Genus_Alistipes
OTU_458_Genus_Lachnospiraceae UCG-008
OTU_59_Genus_Lachnospiraceae NC2004 group
OTU_17_Genus_Fusicatenibacter
OTU_1004_Genus_Pseudobutyrivibrio
OTU_303_Genus_Lachnospiraceae UCG-008
OTU_704_Genus_Collinsella
OTU_106_Genus_Blautia
OTU_72_Genus_Lachnoclostridium
OTU_4_Genus_Bacteroides
OTU_33_Genus_Roseburia
OTU_46_Genus_Incertae Sedis
OTU_11_Genus_Blautia
OTU_133_Genus_Flavonifractor
OTU_1045_Genus_Roseburia
OTU_799_Genus_Roseburia
OTU_764_Genus_Veillonella
OTU_128_Genus_[Eubacterium] hallii group
Dietary intake Dietary intake
Carbohydrates (%TDEI)
Carbohydrates (g)
Dietary fibre (g)
Fat (%TDEI)
Fat (g)
MUFA (%TDEI)
NMES (%TDEI)
NSP (%DRV)
NSP (g)
Protein (%RNI)
Protein (%TDEI)
Protein (g)
PUFA (%TDEI)
SFA (%TDEI)
Starch (%TDEI)
Sugars (%TDEI)
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-0.2
0
0.2
0.4
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OTU_91_Genus_Blautia
OTU_53_Genus_Clostridium sensu stricto 1
OTU_40_Genus_Enterorhabdus
OTU_113_Genus_Clostridium sensu stricto 1
OTU_100_Genus_Ruminococcaceae UCG−004
OTU_41_Genus_Intestinibacter
OTU_47_Genus_[Eubacterium] coprostanoligenes group
OTU_2_Genus_Bifidobacterium
OTU_96_Genus_Ruminococcus 1
OTU_8_Genus_Ruminococcus 2
OTU_119_Genus_Family XIII AD3011 group
OTU_413_Genus_[Ruminococcus] gauvreauii group
OTU_76_Genus_Coprococcus 1
OTU_36_Genus_Streptococcus
OTU_761_Genus_Bifidobacterium
OTU_513_Genus_Blautia
OTU_20_Genus_Bacteroides
OTU_28_Genus_Bacteroides
OTU_568_Genus_Bifidobacterium
OTU_6_Genus_Dialister
OTU_54_Genus_Lachnoclostridium
OTU_12_Genus_Subdoligranulum
OTU_35_Genus_Blautia
OTU_655_Genus_Bacteroides
OTU_88_Genus_Bacteroides
OTU_37_Genus_Succiniclasticum
OTU_662_Genus_Prevotella 9
OTU_114_Genus_Coprococcus 2
OTU_298_Genus_Lachnoclostridium
OTU_1105_Genus_Prevotella 9
OTU_258_Family_Lachnospiraceae
OTU_110_Genus_Ruminococcus 1
OTU_94_Genus_Christensenellaceae R−7 group
OTU_31_Genus_Megamonas
OTU_99_Genus_Senegalimassilia
OTU_97_Genus_Megasphaera
OTU_527_Genus_Alloprevotella
OTU_120_Genus_Lachnospiraceae UCG−005
OTU_57_Genus_Lachnospira
OTU_1049_Genus_Lachnoclostridium
OTU_45_Genus_Parabacteroides
OTU_130_Genus_Christensenellaceae R−7 group
OTU_18_Genus_Phascolarctobacterium
OTU_101_Genus_Anaerotruncus
OTU_868_Genus_Bacteroides
OTU_154_Genus_Odoribacter
OTU_143_Genus_Ruminococcus 1
OTU_194_Genus_Ruminiclostridium
OTU_619_Genus_Hungatella
OTU_70_Genus_Ruminococcaceae UCG−014
OTU_111_Genus_Blautia
OTU_58_Genus_Alloprevotella
OTU_84_Genus_Enterorhabdus
OTU_26_Genus_Coprococcus 3
OTU_5_Genus_Phascolarctobacterium
OTU_7_Genus_Collinsella
OTU_63_Genus_Blautia
OTU_52_Genus_Ruminococcus 1
OTU_30_Genus_Intestinibacter
OTU_132_Genus_Gordonibacter
OTU_92_Genus_Lachnospiraceae FCS020 group
OTU_151_Genus_Turicibacter
OTU_59_Genus_Lachnospiraceae NC2004 group
OTU_61_Genus_Roseburia
OTU_42_Genus_Methanobrevibacter
OTU_67_Genus_Christensenellaceae R−7 group
OTU_102_Genus_Ruminococcaceae UCG−005
OTU_576_Genus_Akkermansia
OTU_115_Genus_Parasutterella
OTU_124_Genus_Ruminiclostridium 6
OTU_68_Genus_Ruminococcaceae UCG−005
OTU_19_Genus_Ruminococcaceae UCG−002
OTU_50_Genus_Tyzzerella 4
OTU_1104_Genus_Akkermansia
OTU_55_Genus_[Eubacterium] coprostanoligenes group
OTU_704_Genus_Collinsella
OTU_38_Genus_[Eubacterium] coprostanoligenes group
OTU_56_Genus_Ruminiclostridium 5
OTU_118_Genus_Terrisporobacter
OTU_1044_Genus_[Eubacterium] hallii group
OTU_893_Genus_[Eubacterium] hallii group
OTU_1036_Class_Bacteroidetes VC2.1 Bac22
OTU_895_Genus_Barnesiella
OTU_51_Genus_Ruminococcaceae UCG−014
OTU_149_Genus_Lachnospiraceae NK4A136 group
OTU_11_Genus_Blautia
OTU_1045_Genus_Roseburia
OTU_4_Genus_Bacteroides
OTU_49_Genus_Alistipes
OTU_138_Genus_Barnesiella
OTU_34_Genus_Bacteroides
OTU_123_Genus_Haemophilus
OTU_29_Genus_Christensenellaceae R−7 group
OTU_104_Genus_Incertae Sedis
OTU_89_Genus_Faecalibacterium
OTU_43_Genus_Veillonella
OTU_183_Genus_[Eubacterium] ventriosum group
OTU_128_Genus_[Eubacterium] hallii group
OTU_95_Genus_Ruminiclostridium
OTU_303_Genus_Lachnospiraceae UCG−008
OTU_48_Genus_Lachnospiraceae UCG−008
OTU_112_Class_Bacteroidetes VC2.1 Bac22
OTU_33_Genus_Roseburia
OTU_799_Genus_Roseburia
OTU_106_Genus_Blautia
OTU_72_Genus_Lachnoclostridium
OTU_46_Genus_Incertae Sedis
OTU_66_Genus_Ruminococcaceae UCG−005
OTU_60_Genus_Bacteroides
OTU_302_Genus_Eisenbergiella
OTU_122_Genus_Ruminiclostridium 9
OTU_881_Genus_Faecalibacterium
OTU_98_Family_Ruminococcaceae
OTU_622_Genus_Lachnospiraceae UCG−001
OTU_86_Genus_Alistipes
OTU_141_Family_Lachnospiraceae
OTU_82_Genus_Lachnospiraceae ND3007 group
OTU_9_Genus_Pseudobutyrivibrio
OTU_458_Genus_Lachnospiraceae UCG−008
OTU_1004_Genus_Pseudobutyrivibrio
Dietary intake Dietary intake
Biscuits, Cakes
Bread
Breakfast Cereals
Desserts
Fish
Fruit
Juice, Other Drinks
Meat, Poultry
Milk, Dairy Products
Potatoes, Pasta, Rice
Savoury Snacks
Sugar, Jam, Spreads
Vegetables
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CD-TREAT
EEN
GFD
[Eubacterium] hallii group
Clostridium sensu stricto 1
Coprococcus 2
Cronobacter
Dialister
Dorea
Eggerthella
Erysipelatoclostridium
Flavonifractor
Intestinimonas
Morganella
Parasutterella
Phascolarctobacterium
Ruminiclostridium 9
Ruminococcaceae NK4A214 group
Ruminococcaceae UCG-002
Ruminococcaceae UCG-005
Ruminococcus 2
Subdoligranulum
Terrisporobacter
Tyzzerella 4
Veillonella
Ruminococcus_1
Eisenbergiella
Family_XIII_AD3011_group
Anaerostipes
Anaerotruncus
Bifidobacterium
Lachnospiraceae_FCS020_group
Escherichia/Shigella
Ruminiclostridium
Pseudobutyrivibrio
Lachnoclostridium
Hungatella
Bilophila
Actinomyces
Anaerofilum
Oscillibacter
Faecalibacterium
Ruminococcaceae_UCG-013
Lachnospiraceae_UCG-004
Candidatus_Soleaferrea
Ruminiclostridium_5
Lactococcus
Butyricimonas
Tyzzerella_4
Senegalimassilia
Ruminiclostridium_6
Ruminococcaceae_UCG-002
Ruminococcaceae_UCG-005
Gordonibacter
Alistipes
Ruminococcaceae_UCG-010
Prevotella
Lactobacillus
Desulfovibrio
Ruminococcaceae_UCG-004
Lachnospiraceae_UCG-010
Coprococcus_2
Fusobacterium
Prevotella_9
Ruminococcus_2
Faecalitalea
Holdemanella
Catenibacterium
Granulicatella
Lachnospiraceae_ND3007_group
Tyzzerella_3
Incertae_Sedis
Peptococcus
Lachnospira
Lachnospiraceae_UCG-005
Cloacibacillus
Lachnospiraceae_UCG-001
Megamonas
Haemophilus
Ruminococcaceae_UCG-003
[Eubacterium]_ventriosum_group
Howardella
Blautia
Decrease
Increase
Jo
urn
al 
Pr
e-p
roo
f
Supplementary Table 1: PERMANOVA analysis using Bray-Curtis and unweighted Unifrac distance metrices 
at OTU and genus level  
 Bray-Curtis Unweighted UniFrac 
OTU level 
Overall  p=0.025, R
2
=2.76% p=0.027, R
2
=2.49% 
Within group comparison 
UCD (20) HC (57) p=0.506, R
2
=1.21% p=0.125, R
2
=1.77% 
TCD (45) HC (57) p=0.017, R
2
=2.32% p=0.045, R
2
=1.57% 
UCD (20) p=0.106, R
2
=2.35% p=0.056, R
2
=2.46% 
UCD (13) 6mos GFD (13) p=0.951, R
2
=1.53% p=0.377, R
2
=2.54% 
 12mos GFD (13) p=0.762, R
2
=2.42% p=0.691, R
2
=2.44% 
Siblings (19) TCD (18) p=0.384, R
2
=2.89% p=0.336, R
2
=2.96% 
 HC (57) p=0.745, R
2
=0.97% p=0.183, R
2
=1.67% 
Genus level 
Overall  p=0.026, R2 = 3.0% n/a 
Within group comparison 
UCD (20) HC (57) p=0.515, R
2
 = 1.15% n/a 
TCD (45) HC (57) p=0.013, R
2
 = 2.56% n/a 
UCD (20) p=0.069, R
2
 = 2.77% n/a 
UCD (13) 6mos GFD (13) p=0.998, R
2
=1.28% n/a 
 12mos GFD (13) p=0.904, R
2
=2.21% n/a 
Siblings (19) TCD (18) p=0.296, R
2
=3.21% n/a 
 HC (57) p=0.696, R
2
=0.94% n/a 
OTU: operational taxonomic unit; n/a: not applicable 
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Supplementary Table 2: Bioenv selected OTU that explain part [(a) 92.3% in UCD, TCD and HC, (b) 92% in UCD and TCD, (c) 91.4% in HC 
and TCD children] of the variance in microbiota structure described by the full OTU dataset:  
 
 
a) 
 
"OTU_6:Bacteria;Firmicutes;Negativicutes;Selenomonadales;Veillonellaceae;Dialister;"                                                                       
"OTU_4:Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Bacteroidaceae;Bacteroides;"                                                                       
"OTU_2:Bacteria;Actinobacteria;Actinobacteria;Bifidobacteriales;Bifidobacteriaceae;Bifidobacterium;"                                                       
"OTU_881:Bacteria;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;Faecalibacterium;"                                                                   
"OTU_14:Bacteria;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;Subdoligranulum;"                                                                     
"OTU_33:Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Roseburia;"                                                                           
"OTU_129:Bacteria;Actinobacteria;Coriobacteriia;Coriobacteriales;Coriobacteriaceae;Eggerthella;"                                                           
"OTU_568:Bacteria;Actinobacteria;Actinobacteria;Bifidobacteriales;Bifidobacteriaceae;Bifidobacterium;Bifidobacterium bifidum NCIMB 41171"                  
"OTU_72:Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Lachnoclostridium;"                                                                   
"OTU_655:Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Bacteroidaceae;Bacteroides;"                                                                     
"OTU_35:Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Blautia;"                                                                             
"OTU_20:Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Bacteroidaceae;Bacteroides;"                                                                      
"OTU_458:Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Lachnospiraceae UCG-008;"       
 
b) 
 
"OTU_6*:Bacteria;Firmicutes;Negativicutes;Selenomonadales;Veillonellaceae;Dialister;"                                                                        
"OTU_4*:Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Bacteroidaceae;Bacteroides;"                                                                              
"OTU_2*:Bacteria;Actinobacteria;Actinobacteria;Bifidobacteriales;Bifidobacteriaceae;Bifidobacterium;"                                                                
"OTU_881:Bacteria;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;Faecalibacterium;"                                                                            
"OTU_60*:Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Bacteroidaceae;Bacteroides;"                                                                               
"OTU_14*:Bacteria;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;Subdoligranulum;"                                                                              
"OTU_33*:Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Roseburia;"                                                                                    
"OTU_129*:Bacteria;Actinobacteria;Coriobacteriia;Coriobacteriales;Coriobacteriaceae;Eggerthella;"                                                                    
"OTU_568*:Bacteria;Actinobacteria;Actinobacteria;Bifidobacteriales;Bifidobacteriaceae;Bifidobacterium;Bifidobacterium bifidum NCIMB 41171"                           
"OTU_72*:Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Lachnoclostridium;"                                                                            
"OTU_35:Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Blautia;"                                                                                      
"OTU_20:Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Bacteroidaceae;Bacteroides;"                                                                               
"OTU_10:Bacteria;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;Faecalibacterium;"                                                                             
Jo
ur
al 
Pr
e-p
roo
f
"OTU_57:Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Lachnospira;" 
 
 
 
c)  
 
"OTU_6*:Bacteria;Firmicutes;Negativicutes;Selenomonadales;Veillonellaceae;Dialister;"                                                              
"OTU_4*:Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Bacteroidaceae;Bacteroides;"                                                              
"OTU_2*:Bacteria;Actinobacteria;Actinobacteria;Bifidobacteriales;Bifidobacteriaceae;Bifidobacterium;"                                              
"OTU_60*:Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Bacteroidaceae;Bacteroides;"                                                             
"OTU_14*:Bacteria;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;Subdoligranulum;"                                                            
"OTU_33*:Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Roseburia;"                                                                  
"OTU_129*:Bacteria;Actinobacteria;Coriobacteriia;Coriobacteriales;Coriobacteriaceae;Eggerthella;"                                                  
"OTU_568*:Bacteria;Actinobacteria;Actinobacteria;Bifidobacteriales;Bifidobacteriaceae;Bifidobacterium;Bifidobacterium bifidum NCIMB 41171"         
"OTU_72*:Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Lachnoclostridium;"                                                          
"OTU_655:Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Bacteroidaceae;Bacteroides;"                                                            
"OTU_86:Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Rikenellaceae;Alistipes;"                                                                
"OTU_41:Bacteria;Firmicutes;Clostridia;Clostridiales;Peptostreptococcaceae;Intestinibacter;" 
*Asterisk indicates Bioenv-selected OTUs that partially explain the variance in community structure of UCD vs TCD as well as HC vs TCD; OTU: operational taxonomic unit  
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Supplementary Table 3: OTUs with significantly different relative abundance in faecal samples of UCD, 
TCD and HC 
 Group 
comparison 
BaseMean log2Fold 
Change 
p-value p-value  
(adjusted) 
OTU_60 Bacteroides HC Vs UCD 7.06 -0.23 6.3E-01 7.83E-01 
 HC Vs TCD 
 
122.96 5.17 3.03E-23 2.17E-20 
 UCD Vs TCD 
 
80.26 4.15 1.43E-08 8.46E-07 
OTU_143 Ruminococcus 1 HC Vs UCD 25.1 -2.08 8.85E-04 1.16E-02 
 HC Vs TCD  18.11 -4.37 8.31E-23 2.98E-20 
 UCD Vs TCD  3.30 -2.28 5.05E-08 2.44E-06 
OTU_31 Megamonas HC Vs UCD 39.6 -2.09 4.56E-03 3.55E-02 
 HC Vs TCD  28.46 -4.72 3.43E-21 8.21E-19 
 UCD Vs TCD  4.94 -2.64 3.99E-08 2.12E-06 
OTU_244 Ruminococcus 1 HC Vs UCD 24.72 -1.37 3.2E-02 1.06E-01 
 HC Vs TCD 17.06 -4.26 5.95E-21 1.07E-18 
 UCD Vs TCD 2.15 -1.19 1.28E-03 9.45E-03 
OTU_78 Ruminiclostridium 5 HC Vs UCD 2.71 -0.69 9.89E-02 2.34E-01 
 HC Vs TCD  30.16 4.40 1.54E-20 2.21E-18 
 UCD Vs TCD  44.97 5.09 1.97E-12 5.22E-10 
OTU_42 Methanobrevibacter HC Vs UCD 38.78 -3.84 1.33E-07 1.47E-05 
 HC Vs TCD 29.62 -4.36 1.88E-17 2.24E-15 
 UCD Vs TCD 2.84 -0.51 2.78E-01 4.25E-01 
OTU_114 Caprococcus 2 HC Vs UCD 32.92 -0.25 7.13E-01 8.41E-01 
 HC Vs TCD  38.73 -4.27 2.92E-17 2.99E-15 
 UCD Vs TCD 4.24 -0.79 1.22E-01 2.32E-01 
OTU_70 Ruminicoccaceae  HC Vs UCD 11.29 -3.43 1.28E-07 1.47E-05 
UCG-014 HC Vs TCD  8.89 -3.36 5.94E-14 5.32E-12 
 UCD Vs TCD 1.42 0.07 8.52E-01 n/a 
OTU_120 Lachnospiraceae  HC Vs UCD 4.48 0.63 1.34E-01 2.97E-01 
UCG-005 HC Vs TCD  69.03 3.59 7.21E-13 5.74E-11 
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 UCD Vs TCD  99.05 4.43 3.74E-11 3.43E-09 
OTU_135 Holdemanella HC Vs UCD 21.19 -1.04 1.10E-01 2.55E-01 
 HC Vs TCD  14.82 -3.20 4.31E-12 3.09E-10 
 UCD Vs TCD  5.52 -2.20 3.0E-06 7.23E-05 
OTU_197 Ruminococcaceae HC Vs UCD 8.55 1.18 1.27E-02 5.63E-02 
UCG – 005 HC Vs TCD 22.96 2.76 1.12E-11 7.29E-10 
 UCD Vs TCD 23.17 0.85 1.42E-01 2.56E-01 
OTU_908 Anaerostipes HC Vs UCD 12.70 -0.83 1.60E-01 3.32E-01 
 HC Vs TCD 8.98 -2.66 4.46E-10 2.66E-08 
 UCD Vs TCD 4.04 -1.83 2.57E-04 2.73-03 
OTU_979 Bifidobacterium  HC Vs UCD 45.70 -0.18 7.36E-01 8.59E-01 
Pseudocatenulatum HC Vs TCD 31.04 -2.13 5.39E-09 2.74E-07 
 UCD Vs TCD 19.91 -1.97 3.0E-05 5.69E-04 
OTU_53 Clostridium  HC Vs UCD 200.98 -2.58 1.1E-05 4.04E-04 
sensu stricto 1 HC Vs TCD  239.45 -2.77 5.72E-09 2.74E-07 
 UCD Vs TCD 52.52 0.39 5.09E-01 6.45E-01 
OTU_186  HC Vs UCD 1.35 -0.11 7.66E-01 n/a 
Gastranaerophilales HC Vs TCD 3.42 2.11 5.74E-09 2.74E-07 
 UCD Vs TCD 4.53 2.22 7.91E-05 1.14E-03 
OTU_84 Enterorhabdus HC Vs UCD 7.93 -2.34 1.20E-04 2.54E-03 
 HC Vs TCD  6.52 -2.32 3.29E-08 1.48E-06 
 UCD Vs TCD 1.99 0.02 9.53E-01 9.71E-01 
OTU_174 Catenibacterium HC Vs UCD 1.56 0.70 2.74E-02 n/a 
 HC Vs TCD 3.19 2.04 3.64E-08 1.54E-06 
 UCD Vs TCD 4.47 1.32 1.81E-02 7.2E-02 
OTU_336 Holdemanella HC Vs UCD 7.99 -2.38 6.68E-05 1.76E-03 
 HC Vs TCD 6.59 -2.30 6.27E-08 2.5E-06 
 UCD Vs TCD 2.02 0.06 8.75E-01 9.27E-01 
OTU_776 Bifidobacterium HC Vs UCD 21.81 -2.25 5.29E-04 8.59E-03 
Animalis HC Vs TCD  17.47 -2.50 9.08E-08 3.26E-06 
 UCD Vs TCD 4.47 1.32 1.81E-02 7.2E-02 
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OTU_88 Bacteroides HC Vs UCD 281.31 0.02 9.79E-01 9.82E-01 
 HC Vs TCD  863.13 2.49 1.02E-07 3.48E-06 
 UCD Vs TCD  1,187.7 2.48 2.66E-04 2.77E-03 
OTU_1002 Lachnospira HC Vs UCD 8.97 -1.75 8.59E-04 1.16E-02 
 HC Vs TCD 33.92 2.49 1.08E-07 3.51E-06 
 UCD Vs TCD 45.22 3.23 1.54E-06 3.89E-05 
OTU_28 Bacteroides HC Vs UCD 151.07 -1.06 6.32E-02 1.7E-01 
 HC Vs TCD  728.21 2.57 2.80E-07 8.72E-06 
 UCD Vs TCD  552.60 3.13 1.08E-06 2.85E-05 
OTU_1049 Lachnoclostridium HC Vs UCD 53.35 0.60 3.14E-01 5.04E-01 
 HC Vs TCD  128.17 2.28 8.26E-07 2.28E-05 
 UCD Vs TCD 180.41 1.68 1.09E-02 5.23E-02 
OTU_125 Parabacteroides HC Vs UCD 34.72 -1.85 9.65E-04 1.22E-02 
 HC Vs TCD  116.40 2.28 9.30E-07 2.47E-05 
 UCD Vs TCD  148.10 4.02 3.88E-11 3.43E-09 
OTU_278 Akkermansia HC Vs UCD 4.46 0.34 4.50E-01 6.47E-01 
 HC Vs TCD 15.59 2.17 1.13E-06 2.88E-05 
 UCD Vs TCD 20.63 2.37 1.87E-04 2.2E-03 
OTU_537 Dialister HC Vs UCD 18.0 -2.46 1.10E-04 2.43E-03 
 HC Vs TCD  15.10 -2.20 1.37E-06 3.40E-05 
 UCD Vs TCD 4.68 0.23 6.11E-01 7.29E-01 
OTU_62 Ruminococcaceae  HC Vs UCD 23.89 -3.94 1.84E-08 1.01E-05 
UCG-014 HC Vs TCD  11.97 -2.27 1.69E-06 3.90E-05 
 UCD Vs TCD 3.30 0.88 7.0E-02 1.79E-01 
OTU_752 Subdoligranulum HC Vs UCD 43.81 -1.87 1.49E-03 1.68E-02 
 HC Vs TCD  164.0 2.47 2.72E-06 5.57E-05 
 UCD Vs TCD  122.66 3.48 5.24E-07 1.74E-05 
OTU_99 Senegalimassilia HC Vs UCD 73.24 -3.88 1.05E-07 1.47E-05 
 HC Vs TCD  61.70 -2.47 9.10E-06 1.52E-04 
 UCD Vs TCD 14.06 1.48 2.37E-02 8.5E-02 
OTU_112 Bacteroidetes HC Vs UCD 22.60 -3.07 1.16E-07 1.47E-05 
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 HC Vs TCD 31.79 -1.19 1.0E-02 4.2E-02 
 UCD Vs TCD  13.92 2.42 1.43E-05 3.15E-04 
OTU_1054 Alistipes HC Vs UCD 17.29 -2.95 7.37E-07 6.78E-05 
 HC Vs TCD 30.12 0.81 8.83E-02 2.18E-01 
 UCD Vs TCD 28.41 3.74 1.82E-09 1.38E-07 
OTU_146 Slackia HC Vs UCD 7.95 -3.09 1.02E-06 8.05E-05 
 HC Vs TCD 7.16 -1.73 1.27E-04 1.26E-03 
 UCD Vs TCD 2.57 1.36 9.44E-03 4.91E-02 
OTU_226 [Eubacterium]  HC Vs UCD 5.92 -2.79 2.55E-06 1.76E-04 
oxideroducens group HC Vs TCD 6.68 -0.48 2.6E-01 4.48E-01 
 UCD Vs TCD 4.11 2.37 4.87E-05 8.33E-04 
OTU_45 Parabacteroides HC Vs UCD 56.41 -3.08 3.60E-06 2.21E-04 
 HC Vs TCD 73.21 0.84 1.04E-01 2.47E-01 
 UCD Vs TCD  69.9 3.44 3.06E-07 1.25E-05 
OTU_895 Barnesiella HC Vs UCD 58.0 -3.11 5.04E-06 2.77E-04 
 HC Vs TCD 54.13 -1.48 5.16E-03 2.4E-02 
 UCD Vs TCD 21.56 1.65 1.02E-02 5.03E-02 
OTU_101 Anaerotruncus HC Vs UCD 15.61 -3.11 5.53E-06 2.77E-04 
 HC Vs TCD 17.95 -0.46 3.83E-01 5.67E-01 
 UCD Vs TCD  11.03 2.64 4.55E-05 8.05E-04 
OTU_572 Family XVIII  HC Vs UCD 9.54 -2.43 7.14E-06 3.16E-04 
AD3011 group HC Vs TCD 11.51 -0.19 6.55E-01 7.82E-01 
 UCD Vs TCD 7.94 2.20 6.21E-05 9.70E-04 
OTU_230 Bacteroides HC Vs UCD 6.20 -2.79 7.43E-06 3.16E-04 
 HC Vs TCD 6.79 -0.60 1.79E-01 3.62E-01 
 UCD Vs TCD 4.02 2.18 1.13E-04 1.58E-03 
OTU_65 Bacteroides HC Vs UCD 9.79 -2.44 8.18E-06 3.23E-04 
 HC Vs TCD 25.82 1.73 7.37E-05 1.28E-03 
 UCD Vs TCD  29.9 4.19 1.17E-12 5.22E-10 
OTU_49 Alistipes HC Vs UCD 56.57 -2.40 1.86E-05 6.42E-04 
 HC Vs TCD 174.05 1.50 3.31E-03 1.72E-02 
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 UCD Vs TCD  192.53 4.41 5.95E-12 1.05E-09 
OTU_109 Ruminococcus 2 HC Vs UCD 6.0 -2.54 2.39E-05 7.75E-04 
 HC Vs TCD 5.40 -1.57 2.12E-04 1.88E-03 
 UCD Vs TCD 2.22 0.96 3.83E-02 1.17E-01 
OTU_51 Ruminococcaceae HC Vs UCD 13.48 -2.49 4.88E-05 1.50E-03 
UCG-014 HC Vs TCD 16.15 -0.22 6.38E-01 7.66E-01 
 UCD Vs TCD  11.22 2.25 1.20E-04 1.60E-03 
OTU_111 Blautia HC Vs UCD 23.54 -2.33 6.14E-05 1.7E-03 
 HC Vs TCD 28.78 -0.13 7.87E-01 8.72E-01 
 UCD Vs TCD  20.82 2.19 4.69E-04 4.61E-03 
OTU_868 Bacteroides HC Vs UCD 136.18 -2.64 7.33E-05 1.76E-03 
 HC Vs TCD 293.71 1.33 1.42E-02 5.4E-02 
 UCD Vs TCD  310.64 4.83 8.47E-12 1.12E-09 
OTU_923 Mavinbryantia HC Vs UCD 10.23 -2.00 7.03E-05 1.76E-03 
 HC Vs TCD 13.06 0.07 8.63E-01 9.2E-01 
 UCD Vs TCD 10.29 2.06 2.49E-04 2.7E-03 
OTU_190 Alistipes HC Vs UCD 6.26 -2.16 1.09E-04 2.43E-03 
 HC Vs TCD 11.02 0.07 8.74E-01 9.26E-01 
 UCD Vs TCD 13.20 3.35 5.57E-08 2.46E-06 
OTU_168 Alistipes HC Vs UCD 4.43 -2.01 4.11E-04 7.31E-03 
 HC Vs TCD 3.92 -1.54 8.38E-05 9.40E-04 
 UCD Vs TCD 1.75 0.45 2.5E-02 3.9E-01 
OTU_3 Akkermansia HC Vs UCD 2,041.4 -2.17 1.41E-03 1.63E-02 
 HC Vs TCD 2,863.9 0.33 5.55E-01 7.09E-01 
 UCD Vs TCD 2,466.0 1.45 5.12E-02 1.43E-01 
OTU_1 Prevotella 9 HC Vs UCD 6,760.4 -2.68 3.77E-03 3.15E-02 
 HC Vs TCD 5,953.8 -1.79 1.22E-02 4.84E-03 
 UCD Vs TCD 193.2 0.85 2.36E-01 3.75E-01 
OTU_302 Eisenbergiella HC Vs UCD 26.32 -1.38 1.01E-02 4.74E-02 
 HC Vs TCD 55.97 1.44 7.21E-04 5.23E-03 
 UCD Vs TCD  97.89 3.49 2.47E-09 1.64E-07 
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OTU_259  HC Vs UCD 4.86 -1.71 6.88E-04 1.07E-02 
Erysipelatoclostridium HC Vs TCD 8.45 0.95 1.27E-02 5.0E-02 
 UCD Vs TCD 8.6 2.61 4.31E-07 1.64E-05 
OTU_448 Ruminiclostridium 5 HC Vs UCD 9.97 -1.66 5.36E-05 1.56E-03 
 HC Vs TCD 15.06 0.61 5.6E-02 1.57E-01 
 UCD Vs TCD 13.72 2.20 4.8E-07 1.7E-05 
OTU_270 Butyricimonas  HC Vs UCD 5.25 -1.88 4.56E-04 7.63E-03 
 HC Vs TCD 10.0 1.13 8.16E-03 3.52E-02 
 UCD Vs TCD 10.47 3.00 7.49E-07 2.34E-05 
OTU_248 Clostridium  HC Vs UCD 2.07 -0.77 7.32E-02 1.87E-01 
sensu stricto 1 HC Vs TCD 4.37 1.57 2.49E-05 3.5E-04 
 UCD Vs TCD 7.89 2.96 9.12E-07 2.69E-05 
OTU_317 Lachnospireaceae  HC Vs UCD 3.81 -1.83 1.52E-04 2.89E-03 
NK4A136 group HC Vs TCD 7.29 1.56 4.05E-03 1.99E-02 
 UCD Vs TCD 7.67 2.97 9.99E-07 2.79E-05 
OTU_34 Bacteroides HC Vs UCD 243.37 -1.75 4.11E-03 3.29E-02 
 HC Vs TCD 425.59 0.96 3.8E-02 1.19E-01 
 UCD Vs TCD  431.67 2.72 6.24E-06 1.44E-04 
OTU_235 Lachnospiraceae HC Vs UCD 6.69 -1.52 1.35E-03 1.60E-02 
 HC Vs TCD 10.74 0.79 3.9E-02 1.21E-01 
 UCD Vs TCD 10.62 2.31 1.95E-05 4.15E-04 
OTU_1036 Bacteroidetes HC Vs UCD 59.31 -1.43 3.60E-02 1.14E-01 
 HC Vs TCD 76.45 0.23 6.5E-01 7.8E-01 
 UCD Vs TCD  61.94 2.57 2.07E-05 4.22E-04 
OTU_73 Bacteroides HC Vs UCD 6.31 -1.26 8.05E-03 4.38E-02 
 HC Vs TCD 11.31 1.08 7.24E-03 3.24E-02 
 UCD Vs TCD  12.07 2.32 3.22E-05 5.89E-04 
OTU_154 Odoribacter HC Vs UCD 30.05 -0.95 1.06E-01 2.48E-01 
 HC Vs TCD 61.85 1.48 1.13E-03 7.18E-03 
 UCD Vs TCD  72.08 2.43 5.23E-05 8.68E-04 
OTU_139 Bilophila HC Vs UCD 22.05 -0.67 2.20E-01 3.99E-01 
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 HC Vs TCD 49.71 0.44 9.57E-05 1.01E-03 
 UCD Vs TCD  59.99 2.37 5.65E-05 9.09E-04 
OTU_77 Lachnoclostridium HC Vs UCD 47.57 -0.75 1.61E-01 3.32E-01 
 HC Vs TCD 120.45 1.11 1.82E-02 6.59E-02 
 UCD Vs TCD  128.1 2.40 7.94E-05 1.14E-03 
OTU_343 Christensenellaceae HC Vs UCD 1.84 -0.42 2.68E-01 4.55E-01 
 HC Vs TCD 4.18 1.82 4.55E-07 1.36E-05 
 UCD Vs TCD 4.98 2.14 7.97E-05 1.14E-03 
OTU_355 Lachnoclostridium HC Vs UCD 24.25 -0.88 9.18E-02 2.20E-01 
 HC Vs TCD 43.33 1.19 3.82E-03 1.9E-02 
 UCD Vs TCD 46.44 2.01 1.19E-04 1.60E-03 
OTU_98 Ruminococcaceae HC Vs UCD 58.58 -0.55 3.0E-01 4.9E-01 
 HC Vs TCD 118.5 1.54 1.46E-04 1.36E-03 
 UCD Vs TCD  139.21 2.06 1.39E-04 1.80E-03 
OTU_282 Christensenellaceae HC Vs UCD 4.57 -0.49 3.34E-01 5.24E-01 
 HC Vs TCD 11.23 1.37 1.8E-03 1.1E-02 
 UCD Vs TCD 12.46 2.21 1.59E-04 1.92E-03 
OTU_1104 Akkermansia HC Vs UCD 8.04 -0.82 9.76E-02 2.32E-01 
 HC Vs TCD 17.76 1.65 2.25E-04 1.97E-03 
 UCD Vs TCD  21.41 2.46 1.56E-04 1.92E-03 
OTU_46 Incertae Sedis HC Vs UCD 192.02 -0.67 1.88E-01 3.69E-01 
 HC Vs TCD 480.32 1.09 1.38E-02 6.17E-02 
 UCD Vs TCD  512.68 2.34 1.94E-04 2.24E-03 
OTU_63 Blautia HC Vs UCD 154.0 -0.70 2.24E-01 4.02E-01 
 HC Vs TCD 341.42 1.69 4.03E-04 3.14E-03 
 UCD Vs TCD  415.46 2.33 2.2E-04 2.43E-03 
OTU_176 Lachnoclostridium HC Vs UCD 10.20 -0.71 1.39E-01 3.04E-01 
 HC Vs TCD 19.53 1.37 8.38E-04 5.89E-03 
 UCD Vs TCD 21.77 2.03 2.17E-04 2.43E-03 
OTU_134 Ruminiclostridium HC Vs UCD 30.41 -1.31 9.4E-03 4.59E-02 
 HC Vs TCD 46.6 0.72 7.65E-02 1.94E-01 
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 UCD Vs TCD 45.40 2.02 2.77E-04 2.83E-03 
OTU_136 [Eubacterium] HC Vs UCD 117.66 -1.32 5.59E-02 1.57E-01 
coprostanoligenes group HC Vs TCD 158.56 0.38 4.9E-01 6.54E-01 
 UCD Vs TCD  218.81 2.38 1.57E-03 1.13E-02 
OTU_245 Christensenellaceae  HC Vs UCD 11.55 -0.64 2.71E-01 4.57E-01 
R-7 group HC Vs TCD 23.45 1.52 1.55E-03 9.45E-03 
 UCD Vs TCD 25.55 2.00 2.23E-03 1.54E-02 
n/a: not applicable; log2Fold change is negative when the second group in the pairwise comparison has 
lower relative abundance than the first one; OTU: operational taxonomic unit 
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Supplementary Table 4: OTUs with significantly different relative abundance in faecal samples of (a) paired data 
from 13 CD children at diagnosis and at six and 12 months after the initiation of GFD, and (b) from cross-
sectional data from UCD patients (n=20) and TCD patients (n=45) 
 Group  
comparison 
BaseMean log2Fold 
Change 
p-value p-value  
(adjusted) 
OTU_576 Akkermansia UCD Vs GFD 6 mos 212.2 -8.53 1.79E-05 1.27E-03 
 UCD Vs GFD 12 mos 109.1 -7.00 3.20E-06 1.31E-03 
 UCD Vs TCD 124.9 1.19 1.27E-01 2.38E-01 
OTU_6 Dialister
 
UCD Vs GFD 6 mos 1,428.3 6.82 1.99E-06 2.83E-04 
 UCD Vs GFD 12 mos 1,283.0 6.88 1.48E-05 1.52E-03 
 UCD Vs TCD 1,540.8 -0.21 7.67E-01 8.48E-01 
OTU_5  UCD Vs GFD 6 mos 1,522.3 -9.80 5.98E-11 1.70E-08 
Phascolarctobacterium  UCD Vs GFD 12 mos 1,256.2 -7.66 8.71E-06 1.52E-03 
 UCD Vs TCD 2,385.3 0.83 3.26E-01 4.69E-01 
OTU_537 Dialister  UCD Vs GFD 6 mos 25.8 6.82 2.51E-05 1.42E-03 
 UCD Vs GFD 12 mos 25.9 7.69 1.15E-05 1.52E-03 
 UCD Vs TCD 4.68 0.23 3.11E-01 7.29E-01 
OTU_8 Ruminococcus 2  UCD Vs GFD 6 mos 2,208.9 4.79 6.18E-03 4.46E-02 
 UCD Vs GFD 12 mos 3,458.3 6.24 1.71E-04 1.40E-02 
 UCD Vs TCD 2,692.5 0.21 7.48E-01 8.33E-01 
OTU_43 Veillonella  UCD Vs GFD 6 mos 343.6 4.80 6.14E-04 1.43E-02 
 UCD Vs GFD 12 mos 1,222.8 5.26 3.85E-04 2.26E-02 
 UCD Vs TCD 367.3 -0.42 4.66E-01 6.00E-01 
OTU_55 [Eubacterium]  UCD Vs GFD 6 mos 119.2 6.46 1.39E-03 2.28E-02 
coprostanoligenes group  UCD Vs GFD 12 mos 129.2 6.76 3.69E-04 2.26E-02 
 UCD Vs TCD 86.6 -0.38 5.89E-01 7.09E-01 
OTU_1045 Roseburia   UCD Vs GFD 6 mos 98.6 0.85 5.22E-01 8.06E-01 
 UCD Vs GFD 12 mos 140.7 5.49 5.53E-04 2.52E-02 
 UCD Vs TCD 276.2 -0.27 6.85E-01 7.87E-01 
OTU_50 Tyzzerella 4  UCD Vs GFD 6 mos 59.9 -6.20 1.22E-04 3.84E-03 
 UCD Vs GFD 12 mos 62.6 -5.39 5.08E-04 2.52E-02 
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 UCD Vs TCD 55.6 1.74 5.06E-03 3.02E-02 
OTU_191 Christensenellaceae UCD Vs GFD 6 mos 16.9 6.09 1.01E-04 3.57E-03 
R-7 group UCD Vs GFD 12 mos 17.4 6.00 6.65E-04 2.73E-02 
 UCD Vs TCD 14.4 -0.74 2.07E-01 3.39E-01 
OTU_22 Ruminococcaceae  UCD Vs GFD 6 mos 748.0 3.92 1.29E-03 2.28E-02 
UCG-002  UCD Vs GFD 12 mos 772.1 6.01 8.30E-04 2.84E-02 
 UCD Vs TCD 785.6 -0.22 7.35E-01 8.24E-01 
OTU_18 Phascolarctobacterium  UCD Vs GFD 6 mos 732.0 -0.48 7.88E-01 9.85E-01 
 UCD Vs GFD 12 mos 109.8 -5.38 7.91E-04 2.84E-02 
 UCD Vs TCD 9.4 0.96 1.36E-01 2.46E-01 
OTU_166 Cronobacter UCD Vs GFD 6 mos 25.3 -7.90 5.84E-06 5.53E-04 
 UCD Vs GFD 12 mos 3.57 -0.02 9.91E-01 9.98E-01 
 UCD Vs TCD 3.4 0.65 1.54E-01 2.73E-01 
OTU_113 Clostridium sensu  UCD Vs GFD 6 mos 268.6 5.73 7.91E-05 3.21E-03 
stricto 1  UCD Vs GFD 12 mos 297.8 4.92 2.03E-03 6.43E-02 
 UCD Vs TCD 148.6 0.67 2.78E-01 4.25E-01 
OTU_259  UCD Vs GFD 6 mos 26.8 -6.95 7.37E-05 3.21E-03 
Erysipelatoclostridium UCD Vs GFD 12 mos 10.5 -1.98 2.78E-01 9.98E-01 
 UCD Vs TCD 8.6 2.61 4.31E-07 1.64E-05 
OTU_24 Lachnoclostridium  UCD Vs GFD 6 mos 1,315.9 5.22 2.79E-04 7.91E-03 
 UCD Vs GFD 12 mos 1,471.1 2.51 9.34E-02 6.32E-01 
 UCD Vs TCD 939.0 -0.70 2.28E-01 2.83E-02 
OTU_14 Subdoligranulum  UCD Vs GFD 6 mos 1,006.0 4.16 6.55E-04 1.43E-02 
 UCD Vs GFD 12 mos 1,258.2 2.21 1.30E-01 7.30E-01 
 UCD Vs TCD 1,446.3 1.24 2.59E-02 9.09E-02 
OTU_83 Alistipes  UCD Vs GFD 6 mos 93.9 5.52 6.50E-04 1.43E-02 
 UCD Vs GFD 12 mos 113.2 5.40 9.00E-03 1.83E-01 
 UCD Vs TCD 132.2 0.65 3.06E-01 4.49E-01 
OTU_66 Ruminococcaceae  UCD Vs GFD 6 mos 558.9 4.49 7.20E-04 1.46E-02 
UCG-005  UCD Vs GFD 12 mos 505.6 2.38 1.64E-01 7.98E-01 
 UCD Vs TCD 304.6 0.77 1.55E-01 2.73E-01 
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OTU_98 Ruminococcaceae  UCD Vs GFD 6 mos 57.0 -3.66 8.64E-04 1.63E-02 
 UCD Vs GFD 12 mos 53.1 -1.81 2.57E-01 9.98E-01 
 UCD Vs TCD 139.2 2.06 1.39E-04 1.80E-03 
OTU_3 Akkermansia  UCD Vs GFD 6 mos 1,033.2 5.40 1.45E-03 2.28E-02 
 UCD Vs GFD 12 mos 1,582.8 2.19 2.35E-01 9.95E-01 
 UCD Vs TCD 2,466.0 1.45 5.12E-02 1.43E-01 
OTU_129 Eggerthella UCD Vs GFD 6 mos 73.1 -3.76 2.99E-03 3.14E-02 
 UCD Vs GFD 12 mos 72.6 -1.69 2.12E-01 9.49E-01 
 UCD Vs TCD 70.16 0.53 2.89E-01 4.36E-01 
OTU_893 [Eubacterium]  UCD Vs GFD 6 mos 82.7 -2.95 2.60E-03 3.14E-02 
hallii group  UCD Vs GFD 12 mos 85.3 -1.93 8.97E-02 6.32E-01 
 UCD Vs TCD 50.2 0.48 3.50E-01 4.91E-01 
OTU_303 Lachnospiraceae UCD Vs GFD 6 mos 46.0 -3.69 2.90E-03 3.14E-02 
UCG-008  UCD Vs GFD 12 mos 62.5 -0.42 7.67E-01 9.98E-01 
 UCD Vs TCD 114.8 1.47 3.77E-03 2.47E-02 
OTU_115 Parasutterella  UCD Vs GFD 6 mos 56.8 4.42 2.33E-03 3.14E-02 
 UCD Vs GFD 12 mos 73.4 3.26 4.43E-02 4.54E-01 
 UCD Vs TCD 36.5 1.62 5.14E-03 3.03E-02 
OTU_1005 Fusicatenibacteri UCD Vs GFD 6 mos 9.71 -4.70 2.31E-03 3.14E-02 
 UCD Vs GFD 12 mos 8.7 -2.47 1.28E-01 7.30E-01 
 UCD Vs TCD 4.25 0.11 8.07E-01 8.76E-01 
OTU_133 Flavonifractor  UCD Vs GFD 6 mos 57.0 -3.64 4.45E-03 4.36E-02 
 UCD Vs GFD 12 mos 59.1 -2.48 1.07E-01 6.58E-01 
 UCD Vs TCD 99.5 1.02 5.73E-02 1.55E-01 
OTU_1044 [Eubacterium]  UCD Vs GFD 6 mos 150.3 -3.14 5.18E-03 4.37E-02 
hallii group  UCD Vs GFD 12 mos 149.9 -2.11 1.40E-01 7.58E-01 
 UCD Vs TCD 152.3 0.04 9.38E-01 9.61E-01 
OTU_185 Dorea UCD Vs GFD 6 mos 19.4 4.18 5.41E-03 4.37E-02 
 UCD Vs GFD 12 mos 20.0 3.10 7.03E-02 5.77E-01 
 UCD Vs TCD 6.5 -0.05 9.29E-01 9.56E-01 
OTU_90 Ruminococcaceae UCD Vs GFD 6 mos 103.6 4.71 5.05E-03 4.37E-02 
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UCG-002   UCD Vs GFD 12 mos 92.9 3.83 4.53E-02 4.54E-01 
 UCD Vs TCD 83.8 1.83 1.89E-03 1.34E-02 
OTU_122 Ruminiclostridium 9  UCD Vs GFD 6 mos 25.3 -4.32 5.09E-03 4.37E-02 
 UCD Vs GFD 12 mos 83.1 -4.10 1.70E-02 2.79E-01 
 UCD Vs TCD 16.9 0.20 7.33E-01 8.23E-01 
OTU_15 Dorea  UCD Vs GFD 6 mos 275.7 3.58 6.28E-03 4.46E-02 
 UCD Vs GFD 12 mos 446.8 2.15 1.67E-01 7.98E-01 
 UCD Vs TCD 538.8 0.82 1.62E-01 2.81E-01 
OTU_68 Ruminococcaceae  UCD Vs GFD 6 mos 152.6 5.45 6.19E-03 4.46E-02 
UCG-005  UCD Vs GFD 12 mos 77.5 3.89 4.99E-02 4.88E-01 
 UCD Vs TCD 150.1 1.36 4.10E-02 1.24E-01 
n/a: not applicable; log2Fold change is negative when the second group in the pairwise comparison has 
lower relative abundance than the first one; OTU: operational taxonomic unit 
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 Supplementary Table 5: OTUs with significantly different relative abundance in faecal samples of 18 TCD children and 
their unaffected 19 siblings 
 BaseMean log2Fold 
Change 
p-value p-value  
(adjusted) 
Higher in 
OTU_38 [Eubacterium] coprostanoligenes group 75.9 5.27 3.09E-12 1.88E-09 SIBLINGS 
OTU_107 Prevotella 7 42.2 5.05 7.62E-10 2.32E-07 SIBLINGS 
OTU_111 Blautia 34.0 4.17 4.98E-09 1.01E-06 SIBLINGS 
OTU_62 Ruminococcaceae UCG-014 19.1 4.01 3.05E-08 4.65E-06 SIBLINGS 
OTU_114 Coprococcus 2 12.9 3.85 9.00E-08 1.10E-05 SIBLINGS 
OTU_568 Bifidobacterium bifidum NCIMB 41171 232.0 4.26 2.10E-07 1.72E-05 SIBLINGS 
OTU_135 Holdemanella 10.6 3.39 2.26E-07 1.72E-05 SIBLINGS 
OTU_143 Ruminococcus 1 9.9 3.51 2.18E-07 1.72E-05 SIBLINGS 
OTU_295 Christensenellaceae R-7 group 6.8 3.43 4.18E-07 2.83E-05 SIBLINGS 
OTU_1059 [Eubacterium] coprostanoligenes group 8.5 3.61 2.93E-06 1.79E-04 SIBLINGS 
OTU_228 Faecalibacterium 6.5 3.36 3.61E-06 2.00E-04 SIBLINGS 
OTU_212 Ruminiclostridium 9 7.5 2.73 6.28E-06 3.06E-04 SIBLINGS 
OTU_74 [Eubacterium] ruminantium group 5.7 3.18 6.53E-06 3.06E-04 SIBLINGS 
OTU_78 Ruminiclostridium 5 11.2 -3.08 1.11E-05 4.60E-04 TCD 
OTU_140 Collinsella 6.9 3.13 1.13E-05 4.60E-04 SIBLINGS 
OTU_230 Bacteroides 6.8 -2.84 1.21E-05 4.62E-04 TCD 
OTU_299 [Ruminococcus] gauvreauii group 9.2 -2.72 1.71E-05 6.07E-04 TCD 
OTU_324 Peptococcaceae 4.7 2.60 1.79E-05 6.07E-04 SIBLINGS 
OTU_88 Bacteroides 954.3 -2.89 1.95E-05 6.23E-04 TCD 
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 OTU_665 Ruminococcaceae UCG-014 9.1 3.26 2.20E-05 6.68E-04 SIBLINGS 
OTU_130 Christensenellaceae R-7 group 10.1 2.72 2.67E-05 7.39E-04 SIBLINGS 
OTU_576 Akkermansia 28.4 -3.03 3.18E-05 8.43E-04 TCD 
OTU_80 Ruminococcaceae UCG-014 5.7 2.77 3.39E-05 8.60E-04 SIBLINGS 
OTU_70 Ruminococcaceae UCG-014 5.2 2.75 4.15E-05 1.01E-03 SIBLINGS 
OTU_178 Ruminococcaceae 8.4 2.42 4.96E-05 1.16E-03 SIBLINGS 
OTU_42 Methanobrevibacter 17.2 3.21 5.55E-05 1.25E-03 SIBLINGS 
OTU_908 Anaerostipes 4.3 2.50 7.12E-05 1.46E-03 SIBLINGS 
OTU_85 Bacteroidales S24-7 group 6.5 -2.68 7.21E-05 1.46E-03 TCD 
OTU_272 [Eubacterium] oxidoreducens group 3.4 2.35 7.14E-05 1.46E-03 SIBLINGS 
OTU_180 Ruminiclostridium 5 6.2 2.71 8.01E-05 1.57E-03 SIBLINGS 
OTU_442 Christensenellaceae 3.7 2.44 9.44E-05 1.80E-03 SIBLINGS 
OTU_163 Ruminiclostridium 5 26.9 -2.34 1.12E-04 2.07E-03 TCD 
OTU_33 Roseburia 427.7 -2.68 1.17E-04 2.09E-03 TCD 
OTU_622 Lachnospiraceae UCG-001 52.9 -2.73 1.26E-04 2.20E-03 TCD 
OTU_783 Bacteroides 4.4 -2.05 2.31E-04 3.71E-03 TCD 
OTU_315 Christensenellaceae R-7 group 8.9 2.40 2.25E-04 3.71E-03 SIBLINGS 
OTU_337 Coriobacteriaceae 7.0 2.45 2.31E-04 3.71E-03 SIBLINGS 
OTU_67 Christensenellaceae R-7 group 53.2 2.71 2.56E-04 4.00E-03 SIBLINGS 
OTU_434 Christensenellaceae 3.7 2.19 3.06E-04 4.55E-03 SIBLINGS 
OTU_155 Lachnoclostridium 23.8 -2.56 3.25E-04 4.71E-03 TCD 
OTU_179 Howardella 3.6 2.28 4.45E-04 6.30E-03 SIBLINGS 
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 OTU_441 Thalassospira 3.8 2.13 4.58E-04 6.34E-03 SIBLINGS 
OTU_895 Barnesiella 21.4 -2.62 5.37E-04 7.26E-03 TCD 
OTU_868 Bacteroides 112.1 -2.68 6.00E-04 7.77E-03 TCD 
OTU_704 Collinsella 91.7 -2.16 6.34E-04 7.88E-03 TCD 
OTU_133 Flavonifractor 82.0 -2.07 9.31E-04 1.09E-02 TCD 
OTU_225 Butyrivibrio 3.1 2.03 1.16E-03 1.26E-02 SIBLINGS 
OTU_149 Lachnospiraceae NK4A136 group 25.9 -2.37 1.55E-03 1.58E-02 TCD 
OTU_195 Bacteroides plebeius DSM 17135 12.2 -2.48 1.84E-03 1.81E-02 TCD 
OTU_116 Ruminococcaceae UCG-014 9.2 2.07 2.64E-03 2.40E-02 SIBLINGS 
OTU_1105 Prevotella 9 192.5 3.03 3.33E-03 2.98E-02 SIBLINGS 
OTU_137 Ruminococcaceae UCG-014 6.6 2.08 3.48E-03 3.05E-02 SIBLINGS 
OTU_1049 Lachnoclostridium 181.3 -2.06 4.73E-03 3.60E-02 TCD 
OTU_63 Blautia 388.5 -2.06 4.87E-03 3.66E-02 TCD 
OTU_156 Christensenellaceae R-7 group 58.7 2.25 4.94E-03 3.67E-02 SIBLINGS 
OTU_1054 Alistipes 45.1 -2.01 5.82E-03 4.07E-02 TCD 
OTU: operational taxonomic unit 
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Supplementary Table 6: Faecal metabolites in coeliac disease children with or without recent ingestion of 
gluten, based on GIP results 
 GIP negative (59) GIP positive (12) p* 
Ammonia (*10
-4 
mg/g) 11.2 (1.8) 7.7 (6.1) 0.043 
Free sulphide (μmol/g) 0.11 (0.03) 0.08 (0.01) 0.228 
Total sulphide (μmol/g) 1.2 (0.25) 0.8 (0.08) 0.121 
L-lactic acid (μg/g)   106.4 (30.6) 86.4 (6.5) 0.750 
D-lactic acid (μg/g)  80.5 (8.4) 87.1 (7.5) 0.925 
Total lactic acid (μg/g) 186.9 (33.9) 173.5 (9.1) 0.414 
Acetic acid (μmol/g) 110.2 (9.5) 125.7 (6.1) 0.338 
Propionic acid (μmol/g) 22.8 (3.1) 23.0 (1.7) 0.956 
Butyric acid (μmol/g) 19.3 (3.1) 21.0 (2.2) 0.675 
Valeric acid (μmol/g) 2.5 (0.51) 2.5 (0.19) 0.856 
Isobutyric acid (μmol/g) 3.1 (0.42) 3.0 (0.20) 0.794 
Isovaleric acid (μmol/g) 3.2 (0.49) 2.95 (0.22) 0.640 
Total SCFA (μmol/g) 161.0 (13.3) 178.0 (9.9) 0.722 
Values expressed as mean (SEM); * Mann-Whitney non-parametric test; gluten ingestion indicated by a 
faecal GIP concentration ≥ 0.156μg/g Jo
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